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ABSTRACT 
Christine V. Fontanilla 
 
NEUROPROTECTIVE STUDIES ON THE MPTP AND SOD1 MOUSE MODELS 
OF NEURODEGENERATIVE DISEASES 
 
The main, underlying cause of neurodegenerative disease is the 
progressive loss of neuronal structure or function, whereby central and/or 
peripheral nervous system circuitry is severely and irreversibly damaged, 
resulting in the manifestation of clinical symptoms and signs. Neurodegenerative 
research has revealed many similarities among these diseases: although their 
clinical presentation and outcomes may differ, many parallels in their pathological 
mechanisms can be found. Unraveling these relationships and similarities could 
provide the potential for the discovery of therapeutic advances such that a 
treatment for one neurologic disease may also be effective for several other 
neurodegenerative disorders. There is growing awareness that due to the 
complexity of pathophysiological processes in human disease, specifically 
targeting or inactivating a single degenerative process or a discrete cellular 
molecular pathway may be ineffective in the treatment of these multifaceted 
disorders. Rather, potential therapeutics with a multi-target approach may be 
required to successfully and effectively control disease progression. Recent 
advances in neurodegenerative research involve the creation of animal disease 
models that closely mimic their human counterparts. The use of both toxin- 
vii 
 
exposure and genetic animal models in combination may give insight into the 
underlying pathologic mechanisms of neurodegenerative disorders (target 
identification) leading to the development and screening of prospective 
treatments and determination of their neuroprotective mechanism (target 
validation). Taken together, ideal candidates for the treatment of 
neurodegenerative disease would need to exert their neuroprotective effect on 
multiple pathological pathways. Previous studies from this laboratory and 
collaborators have shown that the naturally-occurring compound, caffeic acid 
phenethyl ester (CAPE), is efficacious for the treatment against 
neurodegeneration. Because of its versatile abilities, CAPE was chosen for this 
study as this compound may be able to target the pathogenic pathways shared 
by two different animal models of neurodegeneration and may exhibit 
neuroprotection. In addition, adipose-derived stem cell conditioned media (ASC-
CM), a biologically-derived reagent containing a multitude of neuroprotective and 
neurotrophic factors, was selected as ASC-CM has been previously shown to be 
neuroprotective by using both animal and cell culture models of 
neurodegeneration. 
     Martin R. Farlow, M.D., Chair 
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CENTRAL HYPOTHESIS 
 
If two neurodegenerative disorder animal models share the same downstream 
underlying pathogenic pathways, then a compound targeting those pathways 
should be beneficial for both animal models.  
 
EXPLORATORY STUDY:  If two different classes of reagents target the same 
downstream pathogenic pathways involved in neurodegenerative disease, then 
these two reagents should be beneficial in the same neurodegenerative animal 
model. 
SECTION 1:  To determine if administering a compound that has effects on 
multiple downstream pathways in beneficial in a neurotoxin-induced animal 
model of neurodegenerative disease. This section tested the first sub-hypothesis 
that CAPE is beneficial in a toxin model of neurodegeneration. 
SECTION 2:  To determine if administering the same compound is beneficial in a 
genetic animal model of neurodegenerative disease. This section tested the 
second sub-hypothesis that CAPE is beneficial in a genetic model of 
neurodegeneration. 
SECTION 3:  To determine if administering a biologically-derived reagent is an 
effective treatment in that genetic animal model of neurodegenerative disease. 
This section is comprised of the pilot study experiments for the proposed 
Exploratory Study, the effect of adipose-derived stem cell conditioned media on a 
genetic animal model of neurodegeneration. 
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CHAPTER 1:  Caffeic Acid Phenethyl Ester Prevents 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-induced Neurodegeneration 
 
1.1.  Rationale 
 Previous studies and preliminary experiments by this laboratory and 
collaborators have demonstrated the efficacy of utilizing a propolis-isolated 
component, caffeic acid phenethyl ester (CAPE), for the treatment of 
neurodegenerative disease by using animal models (Wei et al., 2004); and, the 
exploration of CAPE’s neuroprotective mechanisms have been documented with 
the use of cell culture systems of neuronal death (Wei et al., 2004; Noelker et al., 
2005; Ma et al., 2006). CAPE is posited to be neuroprotective by way of a host of 
protective abilities against neuronal cell death mechanisms commonly shared 
among neurodegenerative disease etiology and progression, including anti-
inflammatory, anti-oxidant, and immunomodulatory properties (Scapagnini et al., 
2011). Because of CAPE’s multi-faceted protective abilities during the disease or 
injured state, the present research in Chapter 1 sought to examine the effects of 
CAPE treatment on an animal model of Parkinson’s disease (PD). The 1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model of PD was utilized to 
examine the effects of CAPE, as this model exhibits consistent 
neurodegeneration and dopaminergic cell loss specific to the brain area of 
interest with minimal-to-no collateral damage to surrounding brain regions, as 
neuronal cell death due to systemically-administered MPTP is found to be 
restricted to the nigrostriatal circuit and not other dopaminergic systems 
2 
 
(Langston and Irwin, 1986). There are currently a very limited number of effective 
treatments available for the human PD patient to curb disease development or 
progression. Additionally, with a projected over-65 U.S. population doubling by 
2030 (http://www.census.gov/population/www/projections/usinterimproj, 
Accessed September 2011) and aging being a significant risk factor for PD 
(Hickey and Stacy, 2011), the development of effective treatments for PD 
becomes increasingly important with every upcoming decade. Results from this 
study would provide evidence for the potential of CAPE treatment for PD-
associated neurodegeneration and determine CAPE’s targets and mechanisms 
of action to further its prospective use in the PD patient.  
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1.2.  Abstract 
 Parkinson’s disease is associated with the loss of dopaminergic neurons 
in the substantia nigra and decreased striatal dopamine levels. This study now 
reports that caffeic acid phenethyl ester (CAPE), an active component of 
propolis, attenuated dopaminergic neurodegeneration and dopamine loss in an 
MPTP mouse model of Parkinson’s disease. The neuroprotective effect of CAPE 
was associated with marked reductions in iNOS and caspase-1 expression. 
Additionally, CAPE inhibited MPP+-induced neurotoxicity in vitro and directly 
inhibited MPP+-induced release of cytochrome c and apoptosis inducing factor 
(AIF) from mitochondria. Thus, CAPE may have beneficial effects in slowing or 
preventing the progression of Parkinson’s disease and other neurodegenerative 
disorders. 
 
 
 
 
CV Fontanilla, Z Ma, X Wei, J Klotsche, L Zhao, P Wisniowski, W Lee, RC Dodel, 
MR Farlow, WH Oertel, Y Du. 2011. Caffeic acid phenethyl ester prevents 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurodegeneration. 
Neuroscience 188:135-41. 
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1.3.  Introduction 
1.3.1.  Parkinson’s Disease 
In 1817, An Essay on the Shaking Palsy by James Parkinson (Parkinson, 
1817) was the first written work describing “paralysis agitans” in 6 patients 
afflicted with this disease (Eyles, 1955) that was renamed by Jean-Martin 
Charcot 60 years later as “Parkinson’s disease” (PD; Morris et al., 1955). PD is a 
common neurodegenerative disorder, second in incidence only to Alzheimer’s 
disease (http://ninds.nih.gov/disorders/parkinsons_disease, Accessed 
September 2011), that is characterized by a progressive loss of dopaminergic 
neurons in the substantia nigra pars compacta (SNpc; Pakkenberg et al., 1991), 
which results in the extrapyramidal motor dysfunction leading to the hallmark 
clinical symptoms of PD – resting tremor, bradykinesia, rigidity, and postural 
instability, including cognitive impairment at later stages of the disease (Antal et 
al., 1998; Leenders and Oertel, 2001; Galvin 2006; Stacy 2009; Hickey and 
Stacy, 2011; Yokoyama et al., 2011).  
PD is strongly associated with aging and incidence increases with age 
(Hickey and Stacy, 2011). Incidence rates of PD quadruple with age when 
comparing individuals between 55 – 65 years of age versus those 85 years and 
older (Baldereschi et al., 2000). The average age of onset is 60 years. Although 
1% of the population older than 60 years are affected (over 1.2 million 
individuals; Fahn and Przedborski, 2010) and nearly 50,000 new cases per year 
are diagnosed in the U.S. alone 
(http://ninds.nih.gov/disorders/parkinsons_disease, Accessed September 2011), 
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it has been difficult to get an accurate number as diagnoses is hampered by the 
lack of definitive tests for PD as well as the presence of misdiagnoses. PD is 
diagnosed in approximately 50% more males than females (Baldereschi et al., 
2000), however aging is the greatest risk factor 
(http://ninds.nih.gov/disorders/parkinsons_disease, Accessed September 2011; 
Hickey and Stacy, 2011).  
 
1.3.2.  Neurochemical and Neuropathological Changes in PD 
The neuropathology of PD is characterized by death of dopaminergic 
neurons residing in the SNpc. Within these degenerating cells, there is 
accumulation of cytoplasmic inclusions (Lewy bodies) that were shown to contain 
alpha-synuclein, parkin, ubiquitin, chaperone proteins, and phosphorylated 
components of the neuronal cytoskeleton (Jellinger, 2009). When approximately 
50% cell death of dopaminergic neurons and 80% depletion of striatal dopamine 
occurs, manifestation of the characteristic primary motor symptoms of PD begins 
(German et al., 1989; Marsen, 1990; Agid, 1991). PD pathophysiology involves 
the progressive disruption of the normal function and anatomy of the basal 
ganglia (Hickey and Stacy, 2011). Under normal, physiologic conditions and 
regardless of the presence of body movements, there is a continuous and 
constant firing of dopaminergic neurons in the SNpc resulting in steady levels of 
dopamine in the striatum, which leads to persistent activation of striatal dopamine 
receptors (Grace and Bunney, 1983, 1984; Venton et al., 2003). In PD, the 
progressive loss of dopaminergic neurons in the SNpc (Hirsch et al., 1988; 
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Fearnley and Lees, 1991) decreases nigro-striatal dopaminergic content and 
signaling via D1 and D2 receptors, resulting in the disinhibition of the external 
globus pallidus (GPe), which leads to disinhibition of the subthalamic nucleus. 
Progressive disruption and degeneration of the dopaminergic nigro-striatal 
pathway permanently alters the neural circuitry of the basal ganglia, causing the 
primary motor symptoms of PD to manifest (Fig 1.1; Hamani and Lozano, 2006; 
Blandini et al., 2000). 
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Adapted from Hamani and Lozano, 2006 
 
 
 
Figure 1.1.  Schematic of the proposed neural network affected by PD.  
 
In PD, neurodegeneration begins in the substantia nigra pars compacta, where 
significant dopaminergic cell death occurs, leading to a decrease in dopamine 
release to the striatum. The characteristic dopamine (DA) loss affects both the 
direct and indirect pathways involving output from the external globus pallidus 
(GPe) and internal globus pallidus (GPi) and substantia nigra reticulata, 
respectively. Disruption of these neural outputs ultimately results in the 
characteristic movement disorders observed in PD. Dotted lines and large block 
arrows represent the major neural pathways affected in PD. 
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1.3.3.  Current Treatments for PD 
Currently, there is no neuroprotective drug available to alter, reverse, or 
slow disease onset or progression (Quinn, 1998). PD drug development is 
immensely challenged due to the expected population doubling of the over-65 
age group by 2030 in the U.S. alone 
(http://ninds.nih.gov/disorders/parkinsons_disease, Accessed September 2011) 
and the lack of specific disease biomarkers or etiology. Because the causes of 
PD initiation are yet unknown, present treatments can only be applied after 
disease onset, when primary motor symptoms have increased in severity and 
significant, irreversible dopaminergic neuronal death has occurred. Since the 
initial description and first diagnosis of PD almost 200 years ago (Parkinson, 
1817; Eyles, 1955; Morris et al., 1955), the currently available treatments for this 
disease are only directed towards the alleviation of both the primary motor and/or 
late-stage non-motor symptoms of the PD patient.  
The search for novel therapeutics as well as definitive management of 
disease remains elusive at both the basic science and clinical levels. In addition, 
most available treatments are currently unable to address the permanent 
neuronal death that occurs in PD, and a majority only target one aspect of the 
disease’s neuronal death mechanisms. Nevertheless, drug discovery research 
over the years continues to add to the repertoire of information on PD and its 
underlying neuronal death mechanisms.  
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1.3.3.1.  Drug Treatments 
1.3.3.1.1.  L-3,4-dihydroxyphenylalanine 
 L-3,4-dihydroxyphenylalanine (L-dopa) therapy is currently the most 
widely used and most successful treatment for PD, especially for patients in the 
early stages of the disease (Hoehn, 1992). L-Dopa can be administered 
intravenously, via enteral infusion, or orally. Active transport allows this dopamine 
precursor to cross the blood-brain barrier (Kincses and Vescei, 2011). L-Dopa is 
usually given concurrently with a peripheral decarboxylase inhibitor and/or a 
cathechol-O-methyl transferase inhibitor in order to block conversion of L-dopa to 
dopamine in the periphery and peripheral inactivation of L-dopa, respectively, 
resulting in the maintenance of dopamine bioavailability (Hoehn, 1992; Lyons 
and Pahwa, 2006; Wichers et al., 2008). Although treatment with L-dopa 
alleviates the motor symptoms of PD by way of providing a peripherally-
administered source of dopamine to a dopamine-depleted environment, this 
treatment was found to be associated with motor and psychiatric side effects 
(Merello et al., 1996). Most importantly, it is unable to prevent the death of 
dopaminergic neurons. 
 
1.3.3.1.2.  Monoamine Oxidase B Inhibitors 
 The physiologic function of monoamine oxidases is to catalyze the 
oxidative deamination of monoamines, such as dopamine. These enzymes are 
embedded in the outer membrane of the mitochondrion, where they play key 
roles in dopamine degradation (Edmondson et al., 2004; Tipton et al., 2004). The 
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B isoenzyme, monoamine oxidase B (MAO-B), is the more prevalent form of 
monoamine oxidase present in the neurons and glial cells of the human central 
nervous system (Edmondson et al., 2007). Irreversible inhibitors of MAO-B, 
selegiline and rasagiline, were found to have neuroprotective effects in animal 
models of PD (Kupsch et al., 2001; Blandini et al., 2004) via blockage of 
monoamine oxidase activity. However, most drugs targeting preservation of 
dopamine levels in the brain do not prevent the neuronal death observed in PD. 
 
1.3.3.1.3.  Dopamine Agonists 
 Dopamine agonists directly stimulate dopamine receptors by binding to 
them in place of dopamine (Stacy and Galbreath, 2008). This functional aspect 
presents a clear advantage over therapies such as L-dopa as dopaminergic 
receptors can be directly activated in the absence of dopamine and the effects of 
these agonists is independent of the existing population of dopaminergic neurons 
and dopamine metabolism (Kincses and Vecsei, 2010). Dopamine agonists have 
demonstrated neuroprotection in animal and cell culture models of 
neurodegeneration by reducing components responsible for oxidative stress, 
such as free radicals, via upregulation of enzymes with anti-oxidative function 
(Kondo et al., 1994; Ogawa et al., 1994; Nishibayashi et al., 1996; Finotti et al., 
2000; Yoshioka et al., 2002). However, regarding treatment of the PD patient, 
there is modest benefit for symptoms versus L-dopa and a higher incidence of 
impulse control disorders, which can have significant negative consequences on 
the life of the PD patient (Driver-Dunckley et al., 2003; Weintraub et al., 2006; 
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Evans et al., 2009; Weintraub et al., 2010). Although dopamine agonists can help 
maintain the dopaminergic neurocircuitry in the PD patient regardless of the 
presence of dopamine level reduction and the amount of dopaminergic neuron 
loss, these compounds do not alter or block the underlying neuronal death. 
 
1.3.4.  Caffeic Acid Phenethyl Ester 
Caffeic acid phenethyl ester (CAPE) is a naturally-derived polyphenolic 
compound and the biologically active component isolated from propolis, which is 
a popular folk medicine derived from conifer tree bark and is utilized by 
honeybees for hives (Grunberger et al., 1988; Natarajan et al., 1996; Nagai et al., 
2003; Scapagnini et al., 2011). CAPE is small and lipid soluble with structural 
similarity to the flavonoids (Spencer, 2008; Korish and Arafa, 2011). Because of 
its lipophilicity, CAPE can easily cross cell membranes and enter cells upon 
systemic administration, such as intraperitoneal injection (Yildiz et al., 2009). 
Several studies have shown that CAPE has anti-inflammatory, anti-oxidant, and 
immunomodulatory properties (Grunberger et al., 1988; Su et al., 1991, 1994; 
Michaluart et al., 1999; Russo et al., 2002; Son and Lewis, 2002; Wei et al., 
2004; Tan et al., 2005; Iraz et al., 2006; Gokce et al., 2009; Aygun et al., 2011; 
Gocer and Gulcin, 2011; Korish and Arafa, 2011).  
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Figure 1.2.  CAPE chemical structure.  
 
Studies utilizing fluorine substitution for hydrogens in CAPE were designed to 
evaluate CAPE derivatives and their cytoprotective activity. It was observed that 
the 3’ and 4’ hydroxyl (-OH) groups within CAPE’s catechol ring were important 
for the compound’s anti-oxidant ability (Wang et al., 2010). 
 
 
One posited property underlying CAPE’s numerous protective biological 
activities is its ability to inhibit the nuclear transcription factor, nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB; Natarajan et al., 1996; 
Orban et al., 2000; Lee et al., 2010). The exact mechanism by which CAPE 
inhibits NF-κB is currently unknown. NF-κB plays an important transcriptional role 
in the regulation of genes involved in inflammation and immune function (Li and 
Verma, 2002). Under non-pathologic conditions, the NF-κB protein heterodimer 
(Urban et al., 1991) is sequestered in the cytosol in an inactive state and bound 
to inhibitor of κB (IκB). Upon stimulation by pathogenic signals, such as pro-
inflammatory or oxidative stress conditions outside the cell, IκB is phosphorylated 
by IκB kinase and subsequently degraded, allowing for the release and nuclear 
translocation of NF-κB (Natarajan et al., 1996). Within the nucleus, NF-κB activity 
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leads to the production of biological mediators responsible for immune function 
and inflammation, such as pro-inflammatory cytokines, acute phase proteins, 
chemokines, and enzymes including nitric oxide synthase (Li and Verma, 2002; 
Liu and Malik, 2006). The ability of CAPE to inhibit NF-κB activation (Natarajan et 
al., 1996) makes it an attractive candidate for therapeutic intervention of immune 
and inflammatory responses in disease or injured states (Calzado et al., 2007; 
Korish and Arafa, 2011). 
Another ability posited to be responsible for CAPE’s protective effects is 
the induction of heme oxygenase-1 (HO-1; Scapagnini et al., 2002; Wang et al., 
2010; Scapagnini et al., 2011). Activation of the Keap1/Nrf2/ARE pathway by 
CAPE results in HO-1 upregulation (Wang et al., 2010). As with NF-κB inhibition, 
the specific mechanism by which CAPE activates the Keap1/Nrf2/ARE pathway 
is not clearly defined; however, it is suggested that CAPE may directly react with 
Kelch-like ECH-associated protein 1 (Keap1), whose normal function is bind to 
and sequester nuclear factor E2-related factor 2 (Nrf2) in the cytosol, thereby 
inhibiting Nrf2’s function as a nuclear transcription factor (Itoh et al., 1999). 
Posited reaction of CAPE with Keap1 could create a conformational change in 
Keap1, allowing for the release of Nrf2 and its nuclear translocation and binding 
to the antioxidant response element (ARE). Upon binding of Nrf2 to ARE, 
activation of transcription for phase II antioxidant genes, such as the HO-1 gene, 
occurs (Dinkova-Kostova et al., 2002; Wakabayashi et al., 2004). HO-1 plays a 
key role in the cell’s response against oxidative stress and is highly inducible in 
astrocytes and neurons. The HO-1 system exerts its protective effects against 
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neuronal death via anti-inflammatory and anti-oxidative events (Le et al., 1999; 
Chen et al., 2000). HO-1 induction results in the release of bioactive agents that 
have been shown to have powerful anti-oxidant behavior (Stocker et al., 1987; 
Baranano et al., 2002; Otterbein et al., 2003).  
 
1.3.4.1.  CAPE and Neuroprotection 
This laboratory has previously demonstrated that CAPE blocks hypoxia-
ischemia-induced neuronal death through inhibition of neuroinflammation and 
mitochondrial cytochrome c release (Wei et al., 2004). Additional studies from 
this laboratory have shown the efficacy of in vitro CAPE treatment in the 6-
hydroxydopamine (6-OHDA) cell culture model of neurodegeneration, whereby 
neuroprotection is reflected in the reduction of free radical generation, a hallmark 
of this neurotoxin culture model and its underlying neuropathologic events 
(Noelker et al., 2005; Ma et al., 2006). 
Previous studies (See 1.3.3. Caffeic Acid Phenethyl Ester) have 
demonstrated that CAPE protects cells through its anti-inflammatory properties 
via inhibition of NF-κB and its anti-oxidant ability by way of HO-1 induction. 
Despite CAPE’s success with reducing injury-induced neuronal cell death as 
demonstrated in an animal model of hypoxia-ischemia (Wei et al., 2004) and 
confirmation of its neuroprotection using cell culture systems of neuron cell death 
(Noelker et al., 2005; Ma et al., 2006), to date, CAPE’s effects in a PD animal 
model of neurodegeneration have not been tested. Because PD and other 
neurodegenerative diseases, such as amyotrophic lateral sclerosis and hypoxia-
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ischemia, share common downstream degenerative pathways leading to 
neuronal death, including neuroinflammation and oxidative damage, it is of 
interest to this lab to explore the effects of CAPE in a PD animal model and to 
determine whether its anti-oxidant and anti-inflammatory ability play roles in its 
neuroprotection. 
 
1.3.5.  Animal Models of PD 
Animal models of disease serve two major purposes; they have 
mechanistic value for examination of disease etiology and/or progression and 
they are also the first line of testing for a prospective treatment. Prior to the 
1980s, the development of experimental animal models of PD focused on 
decreasing the levels of dopamine in the striatum as a pathological hallmark of 
the disease is dopamine depletion in the brain (Scherman et al., 1989). The 
major disadvantage of these models was that although they allowed for the 
alteration of dopamine content in the brain via chemical or mechanical 
manipulation, which was known to result in the development of the primary motor 
dysfunction observed in the PD patient, and paved the way for use of L-dopa in 
PD patients (Carlsson et al., 1957), these models did not accurately reproduce 
PD brain pathology (Bezard and Przedborski, 2011), such as the death of 
dopaminergic neurons (Marsden 1990; Fearnley and Lees, 1991). Although 
these earlier pharmacological animal models produced behavioral changes 
reminiscent of PD without the associated neuronal death (Carlsson et al., 1957; 
Windle and Cammermayer, 1958; Bezard et al., 1998), they paved the way for 
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present neurotoxin-related research by demonstrating that a greater than 60% 
loss of striatal dopamine led to motor behavioral changes (Bezard and 
Przedborski, 2011). 
To date, there is no animal model that fully recapitulates all of the features 
of clinical PD, such as the neuroanatomical, neurochemical, and neurobehavioral 
changes. Additionally, PD is an aging disorder that progresses over a time period 
of decades. Because of these obstacles and the etiology of PD is still unknown, 
there is currently no perfect animal model for this disease. However, PD animal 
model development has significantly advanced with the application of neurotoxin-
induced models, whereby a majority of primary motor symptoms, brain 
biochemical changes, and associated neuropathology of PD became 
reproducible. In addition to inducing dopamine depletion, with these models, 
scientists are now able to induce dopaminergic neuronal death, a key PD feature 
absent in previous animal models.  
 
1.3.5.1.  Neurotoxin Models of PD 
  Previous animal models of PD were successful in replicating the 
neurochemical changes and behavioral symptoms observed in PD, but none of 
these models were able to reproduce dopaminergic neuronal death (Bezard and 
Przedborski, 2011). Although discovery of the 6-hydroxydopamine-lesioned rat 
garnered attention in the 1970s (Ungerstedt, 1968; Ungerstedt and Arbuthnott, 
1970), it was not until the 1980s that neurotoxin-induced animals entered 
prominence in the modeling of PD. The advantage of neurotoxin models is that 
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they can specifically alter or induce the degeneration of a selected region of 
neuronal populations. If a brain area is known to be affected by a particular 
neurologic disease, that region can then be targeted for degeneration by a 
neurotoxin. Additionally, there are reports supporting neurotoxin use to induce 
neurodegeneration as environmental toxin exposure has been found to play a 
role in development of sporadic PD (Hageman et al., 1999; Di Monte, 2001; 
Gash et al., 2008; Tanner et al., 2009; Cannon and Greenamyre, 2010). 
 
1.3.5.1.1.  6-Hydroxydopamine Model 
The 6-hydroxydopamine (6-OHDA) is one of the oldest, and widely used, 
PD models still in use today (Dauer and Przedborski, 2003; Cannon and 
Greenamyre, 2010). It is also the first animal model demonstrating neurotoxin-
induced dopaminergic neuronal death in the substantia nigra pars compacta 
(SNpc; Ungerstedt, 1968).  
The chemical structure of 6-OHDA is similar to that of dopamine and this 
neurotoxin is selective for monoamine neurons via uptake by dopamine and 
noradrenergic transport systems (Schwarting and Huston, 1996; Luthman et al., 
1998; Bezard et al., 1998). The additional hydroxyl group contributes to its 
toxicity to monaminergic neurons. 6-OHDA cannot cross the blood-brain barrier, 
and in order to target the nigrostriatal pathway, local stereotaxic infusion into the 
striatum or median forebrain bundle, or directly into the substantia nigra, is 
required for its neurotoxic ability (Javoy et al., 1976; Schwarting and Huston, 
1996; Cannon and Greenamyre, 2010). Upon entry into catecholaminergic 
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neurons, 6-OHDA accumulates in the cytosol where it is auto-oxidized and 
damages cells via reactive oxygen species (ROS) formation and oxidative stress 
(Deumens et al., 2002; Orth and Tabrizi, 2003). 
The advantage of the 6-OHDA model is that the stereotaxic lesion can be 
applied unilaterally, such that the contralateral, unlesioned side serves as an 
internal control for each animal. Another appealing feature is that the extent of 
unilateral lesion-induced damage can be assessed behaviorally by observing 
asymmetric circling of the injected animal (Przedborski et al., 1995). A 
disadvantage of the 6-OHDA model is that it must be directly administered to the 
target site or a distal site with projections to the brain region of interest. 
Additionally, administration of 6-OHDA requires stereotaxic surgery, which may 
be difficult to perform in smaller animals, such as mice (Cannon and 
Greenamyre, 2010). Despite the potential technical difficulties of neurotoxin 
administration, the 6-OHDA model can exhibit dopaminergic neuron death, 
depletion of striatal dopamine, and some motor deficits associated with PD 
(Schwarting and Huston, 1996). 
 
1.3.5.1.2.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Model 
 Because Chapter 1 of this thesis work is focused on the MPTP model, 
please see Section 1.3.7. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse 
Model of PD. 
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1.3.5.1.3.  Rotenone Model 
 The rotenone model was the first animal model that provided a link 
between environmental toxin exposure and α-synuclein-containing Lewy body-
like inclusions in surviving dopaminergic neurons (Betarbet et al., 2000). 
Rotenone is found in the roots of several tropical plant species and a widely used 
pesticide and fish poison (Cannon and Greenamyre, 2010). Rotenone is highly 
lipophilic and rapidly and readily crosses the blood-brain barrier (Talpade et al., 
2000). This neurotoxin was shown to inhibit mitochondrial complex I and binds to 
the same site as MPP+. However, unlike MPTP, rotenone-induced inhibition of 
complex I is systemic and not specific to catecholaminergic neurons (Betarbet et 
al., 2000). In addition, the produced lesions were not specific for dopaminergic 
neurons (Ferrante et al., 1997; Cannon and Greenamyre, 2010). The major 
disadvantages of the rotenone model are that it exerts a more widespread, 
nonspecific inhibition of mitochondrial complex I, its use in small animals can be 
technically difficult (Betarbet et al., 2000), and a link between environmental 
rotenone exposure and development of PD in humans remains unclear. 
 
1.3.5.1.4.  Paraquat Model 
Paraquat is a widely used herbicide. Because of its presence in the 
environment, paraquat gained attention as a possible contributor to the 
development of or increased risk for sporadic PD (Liou et al., 1997). Paraquat 
has a structure similar to MPP+, except that paraquat has an additional N-methyl-
pyridinium group instead of the phenyl group found on MPP+ (Dauer and 
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Przedborski, 2003). Unlike MPP+, paraquat’s neuron damaging action is not 
through inhibition of mitochondrial complex I (Richardson et al., 2005), but via 
superoxide formation and oxidative stress (Day et al., 1999; Chun et al., 2001). 
The advantage of using paraquat for modeling PD neurodegeneration is that 
systemic administration results in dopaminergic neuron death and the formation 
of α-synuclein-containing proteinaceous inclusions in the substantia nigra 
(Manning-Bog et al., 2002; McCormack et al., 2002). However, current 
epidemiological evidence and experimental data do not provide support for a 
clear link between paraquat exposure and the development of PD or higher risk 
for PD in humans or that paraquat directly causes brain lesions (Berry et al., 
2010). 
 
1.3.6.  In Vitro Models To Study Neurodegenerative Mechanisms 
 While animal models of PD can provide information on the effectiveness of 
a potential treatment and are more appropriate for addressing the complex 
features of clinical disease, cell culture systems are better suited for determining 
the mechanisms of disease and/or a prospective treatment’s mode of action. As 
with animal models, there is presently no in vitro system that fully recapitulates 
the cellular population and microenvironment within the human PD patient brain. 
Despite each culture system’s limitations and disadvantages, the mechanistic 
data afforded by these models can still function as predictors of what occurs in 
vivo in animal models of PD. This allows for both the identification and pre-
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screening of potential treatments as well as examination of the treatments’ 
mechanisms of action. 
Dopaminergic cell lines, such as human neuroblastoma SH-SY5Y (Biedler 
et al., 1978) and murine mesencephalon-derived MN9D cells (Choi et al., 1992), 
are advantageous as they comprise a uniform population of cells and provide a 
relatively easy and replenishable source of dopaminergic neurons. As a good 
alternative to primary neuronal cultures, cell lines allow for certain biochemical 
analyses and other cell number-dependent assays, which would be difficult to 
accomplish with primary cultures as dopaminergic neurons make up less than 
5% of the primary culture population (Collier et al., 2003). 
Studies using the SH-SY5Y cell line have demonstrated that exposure to 
MPP+ (Veech et al., 2000; Gomez et al., 2001) and rotenone (Sherer et al., 2001; 
Borland et al., 2008) resulted in inhibition of mitochondrial complex I of the 
electron transport chain and neuronal death. Treatment with the dopamine 
agonist, pramipexole, was neuroprotective against MPP+-induced toxicity 
(Cassarino et al., 1998; Presgraves et al., 2004), indicating that this cell line 
exhibits similar neuronal death responses to complex I-inhibiting neurotoxins as 
observed in animal models of PD (Langston et al., 1983; Nicklas et al., 1987; 
Gerlach et al., 1991). In addition, treatment with a dopamine transporter (DAT) 
inhibitor, GBR12909 (Presgraves et al., 2004), prevented MPP+-induced 
neuronal death, providing evidence for functional DAT in these immortalized 
cells. Incubation with protein aggregates of α-synuclein induced cell death in 
cultured SH-SY5Y (El-Agnaf et al., 1998) and exposure of these cells to MPP+ 
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increased α-synuclein expression (Gomez-Santos et al., 2002), providing 
evidence for the role of abnormal protein aggregation in PD neuronal death. 
These reports further validate the use of dopaminergic cell lines for exploring the 
mechanisms of PD and the screening of compounds for PD treatment as they 
can replicate the cellular responses to neurotoxins as found in animal model 
brains. However, the major disadvantage of dopaminergic cell lines is inherent in 
their experimentally-manipulated proliferative nature (Collier et al., 2003). These 
cell lines are undifferentiated and require differentiation and have the ability for 
continuous expansion in culture, unlike primary dopaminergic neurons, which are 
terminally differentiated and post-mitotic. While these cell lines behave similarly 
to and express the cellular features characteristic of dopaminergic neurons in 
primary cultures, their undifferentiated (versus differentiated) states remain in 
question when utilizing these cells as a culture model of PD or 
neurodegeneration (Schule et al., 2009). 
Primary cell cultures are directly obtained from brain tissue of embryonic 
or postnatal animals. Primary neuronal cultures derived from animal 
mesencephalon, such rostral mesencephalic neurons (RMN), are advantageous 
over those comprised of specific cell lines as they are authentic and unaltered 
dopaminergic and non-dopaminergic neurons that are cultured in the presence of 
other cell types, including glial cells, normally found within that brain region. 
Additionally, the culturing of primary neurons allows for the isolation of neuronal 
areas containing specific populations of dopaminergic neurons based on the 
dissected brain area (Collier et al., 2003). Culturing dopaminergic neurons within 
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the cellular context of their naturally-occurring microenvironment is of great 
advantage when exploring the effects of neurotoxins and neuroprotective 
compounds on neuronal survival. 
Several studies have demonstrated the use of RMN to examine the effects 
of neurotoxin-induced neuronal death. Mammalian primary neuronal cultures 
isolated from mouse mesencephalon and incubated with MPP+ (Heyer et al., 
1986; Sanchez-Ramos et al., 1986; Lotharius et al., 1999; Du et al., 2001; 
Carrasco and Werner, 2002) or 6-OHDA (Michel and Hefti, 1990; Lotharius et al., 
1999; Von Coelln et al., 2001; Carrasco and Werner, 2002; Ma et al., 2005) 
resulted in neuronal death. Exposure of RMN to MPP+ in culture media also 
reduced endogenous dopamine levels and dopamine uptake in these cells 
(Mytilineou and Cohen, 1985; Beck et al., 1991). These data demonstrate that 
primary neuronal cultures of mesencephalic origin are representative of the 
functional and neurochemical changes occurring in the dopaminergic neurons of 
the neurotoxin-exposed animal brain. 
In addition to primary culture of RMN, cerebellar granule neurons (CGN) 
are also used as a cell culture system of neurodegeneration. CGN cultures, like 
dopaminergic cell lines, are a homogenous population of cells; however, unlike 
cell lines, CGN are primary neuronal cultures derived from brain tissue. Thus, the 
advantage of utilizing CGN for mechanism studies and in vitro screening of 
neuroprotective compounds is that it is an enriched and authentic neuronal 
population.  
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In the MPTP in vivo model, attention has not been focused on the 
cerebellum, as the neurotoxin’s mode of action mainly involves the dopamine 
neuron and its DAT (See also Section 1.3.7.1. 1-Methyl-4-phenyl-1,2,3,6-
tetrahydropyridine). However, there are several reports demonstrating the 
involvement of the cerebellum in MPTP neurotoxicity. In MPTP-exposed mice, 
there is significant loss of Purkinje cells located in the cerebellar cortex (Takada 
et al., 1988). Tracing studies using tritium (3H)-labeled MPTP have shown that 
levels of bound 3H-MPTP are equal to or greater than striatal levels (Bocchetta et 
al., 1985); in addition, cerebellar 14C-MPP+ levels equaled those observed in the 
substantia nigra in monkeys administered 14C-MPTP (Yang et al., 1988). 
Previous studies have reported the sensitivity of CGN to MPP+ (Marini et al., 
1989; Marini and Paul, 1992; Du et al., 2001) and 6-OHDA neurotoxicity (Noelker 
et al., 2005; Ma et al., 2006), such that these toxins were able to induce CGN 
death in culture. Experiments using glial-neuronal co-cultures exposed to MPTP 
demonstrated that while astrocytic viability remained unaffected by MPTP 
exposure or MPP+ formed in the co-culture, the neurotoxins induced CGN death 
(Marini et al., 1989). Because CGN do not express a DAT, it is posited that MPP+ 
may be entering CGN by using the cell’s glutamate uptake system (Balcar and 
Johnston, 1972; Balcar et al., 1977; Young et al., 1988; Marini et al., 1989). 
These in vivo and in vitro data suggest that the cerebellum and its CGN may be 
an under-examined area of MPTP and MPP+ neurotoxicity. 
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1.3.7.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine Mouse Model of PD 
 The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) mouse model 
was utilized in the present study. MPTP is a mitochondrial complex I inhibitor with 
selectivity for dopaminergic neurons (Vila and Przedborski, 2003). MPTP 
administration has been shown to result in significant dopaminergic neuronal 
death that is primarily observed in the substantia nigra pars compacta, a 
midbrain area severely affected in PD, as well as a profound loss of striatal 
dopamine (Heikkila et al., 1984), causing the neurointoxicated mice to replicate 
most motor deficits observed in clinical PD (Vila and Przedborski, 2003). This 
mouse model has been studied extensively and remains one of the most widely 
used neurotoxin animal models of PD. To date, there have been no in vivo 
studies reporting the use or benefit of caffeic acid phenethyl ester in this mouse 
model. 
 
1.3.7.1.  1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin that 
is a byproduct of the synthesis of an opioid analgesic drug, 1-methyl-4-phenyl-4-
propionoxypiperidine (MPPP), a meperidine analog (Przedborski and Vila, 2001). 
MPTP first garnered recognition as a neurotoxin in 1982 when the California 
neurologist, J. William Langston, discovered the link between a contaminant, 
later identified as MPTP, which was found in illicitly-synthesized MPPP, and the 
development of a parkinsonian syndrome in a group of young drug addicts 
(Langston et al., 1983). 
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Upon systemic administration, conversion of MPTP to MPP+ by glia cells 
and serotonergic neurons within the central nervous system (CNS) is required for 
this protoxin to induce neurotoxicity. Its highly lipophilic nature allows it to cross 
the uncompromised blood-brain barrier (Przedborski and Vila, 2003). Once inside 
the CNS, MPTP is taken up by non-dopaminergic cells, where it is metabolically 
converted into the intermediate, 1-methyl-4-phenyl-2,3-dihydropyridinium 
(MPDP+), by the enzyme, monoamine oxidase B (MAO-B; Tipton and Singer, 
1993). Presumed spontaneous oxidation of MPDP+ then facilitates the final 
conversion of MPDP+ to the polar molecule and active neurotoxin, 1-methyl-4-
phenylpyridinium (MPP+), which is then released from the MAO-B-containing cell 
into the extracellular space by a currently unknown mechanism (Fig 1.3; 
Przedborski and Jackson-Lewis, 1998; Przedborski and Vila, 2003). Because 
MPP+ is a polar molecule, it cannot easily pass the cell membrane and gain entry 
into the cell. MPP+ has a high affinity for the dopamine transporter (DAT) and 
depends on the DAT for uptake into the dopaminergic neuron, where it can then 
exert its neurotoxic effects and lead to neurodegeneration (Przedborski and Vila, 
2003). 
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Przedborski and Vila, 2003 
 
Figure 1.3.  Action of MPTP within the central nervous system. 
 
Systemically-administered MPTP readily crosses the blood-brain barrier due to 
its high lipophilicity and enters the brain where it is taken up by non-dopaminergic 
neurons and enzymatically converted to MPDP+ by MAO-B. MPDP+ is 
spontaneously oxidized into MPP+, which then leaves the cell by an unknown 
mechanism. MPP+ gains entry into dopaminergic neurons via the DAT. Once 
inside the cell, MPP+ induces neurotoxicity by way of a variety of pathogenic 
mechanisms leading to dopaminergic cell death and the characteristic signs of 
clinical PD. 
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1.3.7.2.  MPTP and Neurodegeneration 
MPTP selectively destroys dopaminergic neurons in the SNpc, resulting in 
a Parkinson-like syndrome in humans, monkeys, and mice (Tolwani et al., 1999).  
Upon MPTP conversion to MPP+ within the brain, the neurotoxin enters 
dopaminergic neurons where MPP+ is available to bind to vesicular monoamine 
transporters (VMATs) leading to MPP+ sequestration and accumulation within 
synaptic vesicles, bind to and disrupt enzymes in the cytosol, and concentrate 
within mitochondria thus altering the dopaminergic neuron’s adenosine 
triphosphate (ATP) formation (Fig 2.3; Przedborski and Vila, 2003). It is 
suggested that neuronal apoptosis is involved in the acute MPTP model 
(Viswanath et al., 2001) and that mitochondria, cytochrome c, as well as 
apoptosis inducing factor (AIF) play important roles in the MPTP and MPP+ 
models (Du et al., 1997; Mogi et al., 1998; Offen et al., 1998). Recently, it has 
been shown that MPTP administration results in robust gliosis in the SNpc, 
accompanied by upregulation of interleukin-1β (Liberatore et al., 1999) and 
inducible nitric oxide synthase (iNOS) (Knott et al., 2000). Interestingly, mice with 
inhibition of caspase-1 and iNOS were found to be resistant to MPTP 
neurotoxicity (Dehmer et al., 2000; Klevenyi et al., 1999; Liberatore et al., 1999). 
Previous studies from this and other laboratories using the acute MPTP 
mouse model have demonstrated that after 7 days of MPTP exposure, there is a 
significant and stable decrease in the number of neurons positive for tyrosine 
hydroxylase (TH) in the midbrain (Du et al., 2001). It is important to note for the 
present study that a duration of 7 days of MPTP exposure was used as several 
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reports have indicated that the loss of dendritic processes of striatal and nigral 
TH-positive neuronal cell bodies were not permanent and that the recovery of 
striatal and nigral TH-immunoreactivity was observed after MPTP is eliminated 
systemically within 7 days (Ricaurte et al., 1986). 
 
 
 
 
 
 
Przedborski and Vila, 2003 
 
Figure 1.4.  Consequences of MPP+ entry into dopamine (DA) neurons. 
 
Within the dopamine (DA) neuron, MPP+ binds to a vesicular monoamine 
transporter (VMAT), interacts with cytosolic enzymes, or accumulates within the 
mitochondrion. These processes lead to the degeneration of the DA neuron. 
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Figure 1.5.  Proposed mitochondrial-dependent mechanisms of MPTP 
action leading to cell death. 
 
 MPP+ concentrates within the mitochondrion and binds to and disrupts activity of 
complex I of the electron transport chain. The resulting inhibition of the 
respiratory chain decreases ATP formation and increases ROS production with 
both major events leading to DA neuronal cell death. 
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1.3.8.  Mechanisms of PD 
 With the advancement of PD animal model development and the 
comparisons of experimental reports to clinical data, several key mechanisms of 
PD neurodegeneration have been revealed and posited to be responsible for the 
development and progression of PD. These major pathways may act in concert 
or occur separately in succession, but these neuropathogenic mechanisms 
ultimately converge toward the shared outcome of neuronal death. 
 
1.3.8.1.  Mitochondrial Dysfunction and Oxidative Stress 
Oxidative phosphorylation is the metabolic process by which the 
mitochondrion produces energy in the form of adenosine triphosphate (ATP) from 
nutrients, molecular oxygen, and a series of coupled reduction-oxidation 
reactions within the inner mitochondrial membrane, where the necessary 
machinery (electron transport chain) is located and exchange of electrons occurs 
(Kincses and Vecsei, 2011). The electrons transported down the electron 
transport chain may reduce molecular oxygen, resulting in the formation of 
mitochondrial respiration by-products – reactive oxygen species (ROS), such as 
superoxide and hydrogen peroxide, which can then react with other molecules to 
produce damaging hydroxyl radicals or peroxynitrite (Davies, 1995; Dauer and 
Przedborski, 2003; Valko et al., 2007).  
Studies examining the effects of MPTP in animals have shown that 
systemic administration of this neurotoxin results in the inhibition of complex I of 
the mitochondrial electron transport chain. Inhibition of this complex can lead to 
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increased production of ROS, resulting in a cycle of cellular damage, further 
disruption of the mitochondrial electron transport chain, and even more ROS 
formation and oxidative stress within the cell (Langston et al., 1983; Nicklas et 
al., 1987; Gerlach et al., 1991). Additionally, when these events occur within a 
dopaminergic neuron, the potential oxidative stress produced can be 
compounded by the metabolism of dopamine. This physiological event, along 
with dopamine oxidation, has been found to produce ROS and equally-damaging 
quinones (Graham, 1978; Dauer and Przedborski, 2003). Therefore, 
dopaminergic neurons may be inherently more at risk for oxidative damage 
resulting from the actions of mitochondrial respiration by-products, as well as the 
possible resultant reduction in energy/ATP production, and dopamine 
metabolism. 
Clinical data have been correlated with the mitochondrial dysfunction and 
oxidative damage reported in animal models of PD. Decreased complex I activity 
was observed in the PD brain, platelets, and skeletal muscle (Parker et al., 1989; 
Schapira I et al., 1990; Blin et al., 1994; Swerdlow et al., 1996; Greenamyre et 
al., 2001). Additionally, in the SNpc of PD patients, reduced levels of anti-
oxidants, such as glutathione, have been reported (Sian et al., 1994), which 
could lead to aberrant handling or clearing of ROS and subsequent oxidative 
injury. Taken together, the potential susceptibility of dopaminergic neurons to 
oxidative stress and decreased anti-oxidant levels in the brain could contribute to 
dopaminergic neuron death in PD. 
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1.3.8.2.  Neuroinflammation 
Although the role of neuroinflammation in PD is not yet fully understood, 
there are increasing reports evidencing that neuroinflammation may contribute to 
PD pathogenesis and neuronal death. Microglial activation was found to be 
increased in the substantia nigra of MPTP-exposed humans (McGeer et al., 
1988; Langston et al., 1999). Interestingly, brain microglial cells, the resident 
CNS macrophages, are found in highest density within the substantia nigra (Kim 
et al., 2000). In the presence of damage to the CNS, activated microglia and 
astrocytes proliferate quickly, migrate to the site of injury, exhibit changes in their 
morphology (“resting” versus “reactive” shapes), and upregulate a variety of cell 
surface molecules (Floyd, 1999; Raivich et al., 1999a; Raivich et al., 1999b). 
Upon reaching the injured area, reactive microglia and astrocytes release pro-
inflammatory cytokines, which serve to coordinate the immune response within 
the brain. These inflammatory mediators can then induce the production of 
oxidative stress-related molecules, such as ROS and nitric oxide, in other glial 
cells (Hunot et al., 1999).  
Studies utilizing the MPTP model of PD report robust microglial activation 
in substantia nigra and striatum of affected mice (Kohutnicka et al., 1998; 
Kurkowska-Jastrzebska et al., 1999). Increased levels of inducible nitric oxide 
synthase (iNOS), pro-inflammatory cytokines, such as interleukin-6 (IL-6), 
interleukin-1β (IL-1β), cyclooxygenase-2, were observed along with glial 
activation in the brains of MPTP animals (Kohutnicka et al., 1998; Mogi et al., 
1998; Liberatore et al., 1999). Additionally, previous studies from this laboratory 
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(Du et al., 2001) have demonstrated that minocycline, a tetracycline antibiotic 
with anti-inflammatory effects, was able to block the degeneration of nigrostriatal 
dopaminergic neurons in MPTP-exposed mice by preventing glial activation, IL-
1β production, and iNOS induction. These data suggest that neuroinflammation 
may play an important role in neuronal death in the MPTP mouse model of PD. 
In PD, several post-mortem studies have reported the activation of 
astrocytes and microglia (McGeer et al., 1988; Mirza et al., 2000), which was 
associated with significant elevations in the levels of pro-inflammatory cytokines 
in the brain and cerebrospinal fluid (CSF). Some of these inflammation mediators 
included tumor necrosis factor-alpha (TNF-α), IL-6, IL-1β (Mogi et al., 1994a; 
Mogi et al., 1994b; Blum-Degen et al., 1995; Mogi et al., 1996; Hunot et al., 1999; 
Nagatsu et al., 2000), which were also increased in the MPTP mouse brain. In 
particular, an increase in TNF-α-positive glial cells located in the substantia nigra 
were observed in PD post-mortem; this increase in TNF-α immunoreactivity was 
found in conjunction with elevations of this pro-inflammatory cytokine in the PD 
striatum (366%) and CSF (432%; Boka et al., 1994; Mogi et al., 1994b; Hunot et 
al., 1999). Additionally, there was an inverse correlation with PD severity and IL-6 
levels in the CSF of patients (Muller et al., 1998). 
Studies of the MPTP animal model and post-mortem PD patient tissues 
demonstrate a correlation between neuroinflammation, oxidative damage, and 
the subsequent dopaminergic neuronal death characteristic of this disease. 
However, in vivo studies on the use of anti-inflammatory drugs for the treatment 
of the MPTP mouse model have been reported with variable outcomes and 
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effectiveness (Aubin et al., 1998; Kurkowska-Jastrzebska et al., 1999; 
Mohanakumar et al., 2000; He et al., 2001; Teismann and Ferger, 2001; 
Kurkowska-Jastrzebska et al., 2002; Wu et al., 2002). This suggests that 
blockade or attenuation of a single downstream event or the inflammatory 
process alone is not sufficient to prevent dopaminergic neuron death observed in 
PD. A potential candidate for the treatment of this disease would require a wide 
range of neuroprotective action. 
 
1.3.8.3.  Excitotoxicity 
Upon its release from a pre-synaptic cell, glutamate binds to N-methyl D-
aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) receptors, resulting in their activation and excitatory neurotransmission 
(Dingledine et al., 1999). Glutamate is the key excitatory neurotransmitter in the 
vertebrate CNS. Under normal physiologic conditions and in addition to excitatory 
neurotransmission, the interaction between glutamate and its receptors leads to 
activation of voltage-gated ion channels and the influx of extracellular calcium 
into the cell and its mitochondria (McCormack et al., 1990). This influx allows for 
calcium homeostasis during cellular metabolism and oxidative phosphorylation 
within the mitochondria (Greenamyre and Porter, 1994). 
Excitatory amino acid transporters (EAATs) located on neurons and 
surrounding astrocytes are responsible for terminating excitatory 
neurotransmission by removal of glutamate from the synapse and extracellular 
space in order to keep glutamate below excitotoxic levels (Clements et al., 1992; 
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Shigeri et al., 2004). In neurodegenerative disease, the glutamate concentration 
in the synaptic cleft reaches high levels due to abnormalities in glutamate 
clearance (Ankarcrona et al., 1995). Elevations in glutamate levels can lead to 
increased stimulation of NMDA receptors. This intensified excitatory stimulation 
can result in a higher influx of calcium into the cell and its mitochondria as well as 
calcium release from endoplasmic reticular stores (Hertz, 2007). Elevations in 
intracellular and mitochondrial calcium levels have been shown to cause 
abnormalities in the mitochondrial permeability transition pore, leading to the 
neuronal death cascade (Stavrovskaya and Kristal, 2004; Chan et al., 2009). 
In PD, it is posited that dopamine depletion in the midbrain ultimately 
leads to disinhibition of the subthalamic nucleus, which contains excitatory, 
glutamatergic output neurons that project to the dopaminergic neurons of the 
substantia nigra that express glutamate receptors (Rodriguez et al., 1998; See 
also 1.3.2. Neurochemical and Neuropathological Changes in PD). Constant 
excitatory neurotransmission from the subthalamic nucleus could induce 
excitotoxicity in the substantia nigra, particularly in the pars compacta area, 
resulting in the neuronal death of dopaminergic neurons (Blandini et al., 2000; 
Johnson et al., 2009). Studies using the MPTP primate models have shown that 
treatment with excitatory amino acid receptor antagonists is neuroprotective 
(Beal, 1998; Bonsi et al., 2007), further suggesting the role of excitotoxicity in the 
PD neuronal death mechanism. 
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1.3.8.4.  Aggregation of Protein 
The significance and focus of attention towards protein aggregation in PD 
neuropathogenesis came about when components of Lewy bodies in PD, namely 
α-synuclein, were revealed. Mutations in the genes of these Lewy body 
constituents were found in association with the development of familial forms of 
PD, allowing for the engineering of transgenic mouse models of PD (See also 
1.3.5. Mouse Models of PD). Mutations in the α-synuclein gene caused 
autosomal dominant PD (Polymeropoulos et al., 1997) and mutations in parkin 
and DJ-1 were associated with autosomal recessive PD (Kitada et al., 1998; 
Bonifati et al., 2003). Although familial PD makes up a much smaller percentage 
of total PD cases (PD is primarily sporadic; Siderowf and Stern, 2003) and none 
of the transgenic animal models of PD fully recapitulate the disease, these 
studies brought great attention towards the key role of protein aggregation in PD 
neuronal death. 
α-Synuclein has currently unknown physiologic function and exists 
unfolded and in the α-helix conformation (George, 2002). Unlike its β and γ 
counterparts, under pathological conditions, α-synuclein can fold into a β-sheet 
conformation. The assembly of these β-sheets into filaments leads to α-synuclein 
accumulation in nerve tissue and causes neurodegeneration (El-Agnaf et al., 
1998; Lee et al., 2002). Additionally, elevations in α-synuclein protein aggregates 
lead to oligomer formation, which can be toxic to neurons by disrupting normal 
functioning of the lysosome and proteosome (Maguire-Zeiss 2008; Chau et al., 
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2009). Malfunctioning of the lysosome and proteosome then results in 
accumulation of proteins within the neuron. 
Proteinaceous aggregates of α-synuclein have been shown to promote the 
aberrant folding of other proteins (Olanow, 2009), such as the microtubule-
associated protein, tau (Giasson et al., 2003). Interestingly, tau gene 
polymorphisms have been associated with a higher risk for developing PD 
(Martin et al., 2001), suggesting that significant protein aggregation plays a key 
role in the neuronal death observed in PD. Studies with MPTP have documented 
the critical role of α-synuclein and protein aggregation in neuronal death as α-
synuclein null mice exhibited resistance against MPTP-induced dopaminergic 
neurodegeneration (Dauer et al., 2002). Additionally, it has been shown that 
mitochondrial complex I inhibition and oxidative damage following neurotoxin 
(MPTP, rotenone, or paraquat) exposure contribute to α-synuclein relocation 
from the synapse and aggregation and build-up of inclusions within degenerating 
neurons (Fig 1.6; Kowall et al., 2000; Manning-Bog et al., 2002; Sherer et al., 
2003), further suggesting that protein aggregation involving α-synuclein plays a 
critical role in the PD neuronal death pathway. 
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Adapted from Dawson and Dawson, 2003 
 
Figure 1.6. The key role of mitochondrial dysfunction and complex I 
inhibition in PD. 
 
Reports on the MPTP, rotenone, paraquat animal models of PD reveal that the 
mode of pathogenic action of these neurotoxins is inhibition of complex I. 
Disruption of this mitochondrial component sets off a chain of events contributing 
to the neuronal death observed in PD. Complex I inhibition results in 
excitotoxicity and oxidative stress via activation of NMDA receptors and 
increased ROS production, respectively. Further excitotoxicity-induced oxidative 
damage leads to increased protein aggregation and dysfunction of the 
proteosome. The resulting consequence is cell death.  
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1.4.  Experimental Procedures 
 
1.4.1.  Animals and Animal Treatment Protocol 
 Eight-week-old male C57BL/6 mice (Taconic Farms, Inc., Cambridge City, 
IN, USA) were used with procedures and materials approved by the IACUC at 
the Indiana University School of Medicine (Indianapolis, IN, USA). Mice (vehicle, 
n = 15; MPTP, n = 14; 2 mg/kg CAPE, n = 6; 5 mg/kg CAPE, n = 7; 10 mg/kg 
CAPE, n = 9) were administered caffeic acid phenethyl ester (CAPE; 2, 5, or 10 
mg/kg/day; molecular weight = 284.31, Sigma-Aldrich Corp., St. Louis, MO, USA) 
in 33% PEG-400 vehicle (polyethylene glycol-400 diluted in deionized H2O; 
molecular weight = 400, Sigma-Aldrich Corp.) by oral gavage (p.o.) once only at 
1 hour prior to exposures to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP). Vehicle-only, CAPE-only, and MPTP-only groups were included. The 
MPTP-treated groups (MPTP-only and MPTP-CAPE mice) received four 
intraperitoneal (i.p.) injections of 20 mg/kg MPTP-HCl (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine hydrochloride; molecular weight = 209.72, Sigma-Aldrich 
Corp.) in 0.9% saline at 2-hour intervals in a single day (4 injections total) as 
previously described (Du et al., 2001) and sacrificed at 7 days after the last 
MPTP injection (a total of 7 days and 1 hour after CAPE administration). The 
vehicle group received four injections of 0.9% saline in the same time interval as 
MPTP-treated animals. CAPE-only animals (2, 5, or 10 mg/kg/day) were not 
administered MPTP injections. 
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Figure 1.7.  Diagram of the Animal Treatment Protocol used for this study. 
 
 
1.4.2.  TH-immunohistochemistry and Stereological Quantitation of TH-positive 
Neurons 
 After perfusion-fixation with 4% paraformaldehyde in 0.1 M phosphate 
buffer (pH 7.4) and cryoprotection in 30% sucrose/phosphate buffer, the brains 
were frozen in liquid nitrogen and serially sectioned (40 µm) through the entire 
midbrain. Tissue sections were incubated successively with rabbit polyclonal 
anti-tyrosine hydroxylase (anti-TH) antibody (1:2,500; Calbiochem, Cincinnati, 
OH, USA), goat biotinylated-conjugated polyclonal anti-rabbit antibody (1:250; 
Vector Laboratories, Inc., Burlingame, CA, USA) and horseradish-peroxidase 
conjugated avidin/biotin complex (Vector Laboratories, Inc.). Sections were then 
exposed to 3,3′-diaminobenzidine tetrahydrochloride (DAB) for detection. To 
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quantify TH-positive neurons, we utilized the nuclear counterstain, methyl green 
(Vector Laboratories) and the stereological method for counting TH-positive 
neurons as previously described by Du and colleagues (2001).  
 
1.4.3.  Measurement of Dopamine Levels in the Striatum 
 Following the specified animal treatments, the striatum was dissected in 
ice-cold 1X phosphate buffered saline (PBS), frozen on dry ice, and stored at -
80°C. High-performance liquid chromatography (HPLC) with electrochemical 
detection was used to simultaneously measure the concentration of dopamine in 
each sample (Du et al., 2001). 
 
1.4.4.  Measurement of Caffeic Acid Phenethyl Ester in Mouse Tissue 
 C57BL/6 mice were given 10 mg/kg CAPE by oral gavage. Whole brain 
and blood were collected after 1 hour. Levels of CAPE in harvested tissues were 
measured by using HPLC with electrochemical detection as previously described 
(Du et al., 2001). 
 
1.4.5.  Measurement of Monoamine Oxidase Activity in Mouse Brain 
 Monoamine oxidase (MAO) activity was examined in brain samples using 
the Amplex Red Monoamine Oxidase Assay kit (Molecular Probes, Carlsbad, 
CA, USA). Brain tissue was homogenized on ice in a buffer containing 0.3% 
dithiothreitol, 1 mM ATP, 0.1 mM GTP, 0.1 mM Pipes, 0.5 mM MgCl2 , 2 mM 
EGTA, 0.1 mM EDTA, pH 7.2. The homogenate was then treated with 0.5% 
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Triton X-100 at 4°C for 2 hours and centrifuged at 15,000 rpm with an Eppendorf 
microcentrifuge (Fisher Scientific, Pittsburgh, PA, USA) at 4°C for 10 minutes. 
The supernatant was taken as the enzyme source for MAO and was evaluated 
for total protein content (Pierce protein assay kit; Pierce, Rockford, IL, USA). The 
amine oxidase containing 160 µg of supernatant protein was diluted in 1X 
Reaction Buffer and 100 µL of this mixture was used for each reaction. CAPE 
was then added to this mixture at 1 µM, 10 µM, 50 µM, or 100 µM. A positive 
control was prepared by using 10 µM H2O2 in 1X Reaction Buffer. A negative 
control contained 1X Reaction Buffer but no H2O2. A working solution of 400 µM 
Amplex Red reagent with 1 U/mL horseradish peroxidase (HRP) and 2 mM 
substrate was made and added to each microplate well containing the brain 
samples and controls. The reaction microplate was incubated for 30 minutes at 
room temperature and protected from light. Fluorescence was measured using 
excitation at 530 nm and emission at 590 nm. 
 
1.4.6.  Measurement of CAPE and MPP+ Levels in the Midbrain 
 CAPE and MPP+ were determined in brain samples using liquid 
chromatography. The liquid chromatograph utilizes two Water 510 pumps with a 
484 UV detector (Waters, Milford, MA, USA). For CAPE, a 10 µL sample was 
injected into a Beckman ultrasphere C18 column (2.0 x 250 mm; Beckman 
Coulter, Inc., Brea, CA, USA). The mobile phase consisted of 0.1% TFA in water 
(Buffer A) and acetonitrile (Buffer B). The separation used a linear gradient 
segment of 0 minutes 100% A and 12 minutes 52% A. From 13 minutes to 20 
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minutes the mobile phase consisted of 2% A and 98% B. The flow rate was 1.0 
mL/min and the eluent was monitored at 295 nm. For MPP+ (Du et al., 2001), a 
10-µL sample was injected into a Whatman partisil 10 SCX column (2.0 x 250 
mm; Whatman, Inc., Piscataway, NJ, USA). The mobile phase consisted of 90% 
of a solution (pH 2.35) of 0.1 M acetic acid and 75 mM triethylamine and 10 % 
acetonitrile. The flow rate was 1.5 mL/min for the eluent, which was monitored at 
295 nm. Clearly delineated chromatographic peaks with the retention time of 
authentic standards and expected molecular weights were seen after injection of 
brain extracts from treated animals. Analytes were quantified based on the areas 
of these peaks. 
 
1.4.7.  Neuronal Cell Cultures and Assessment of Neuronal Viability 
1.4.7.1.  Cerebellar Granule Neuronal Primary Culture 
 Cerebellar granule neurons (CGN) were prepared from 8-day-old 
Sprague-Dawley rat pups (Harlan Laboratories, Inc., Indianapolis, IN, USA) as 
previously described (Du et al., 2001). Briefly, freshly dissected cerebella were 
dissociated and the cells seeded at a density of 1.2 to 1.5 x 106 cells/mL on poly-
L-lysine-coated dishes in Basal Medium Eagle supplemented with 10% fetal 
bovine serum (FBS), 25 mM KCl, and gentamicin (0.1 mg/mL). Cytosine 
arabinoside (10 µM) was added to the culture medium 24 hours after initial 
plating. All experiments utilized CGN after 7 – 8 days in vitro (DIV). Viable CGN 
were quantified by counting fluorescein (green) positive cells following staining 
with fluorescein diacetate. Propidium iodide, which interacts with nuclear DNA 
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and produces a red fluorescence, was used to identify dead neurons (Du et al., 
2001).  
 
1.4.7.2.  Rostral Mesencephalic Neuronal Primary Culture 
 Primary cultures of rostral mesencephalic neurons (RMN) dissected from 
embryonic day-15 rat embryos (Harlan) were prepared as previously described 
(Du et al., 2001). Briefly, RMN were dissociated using trypsin and DNase I 
(Gibco) and the cells were suspended in Dulbecco's Modified Eagle Medium 
supplemented with Ham F12 nutrient mixture (1:1; Gibco) and 10% FBS. Cells 
were plated in poly-L-lysine (10 µg/mL; Sigma) pre-coated 24-well plates at a 
density of 1 x 105 cells/cm2. After 24 hours, the medium was supplemented with 
10 µM cytosine arabinoside to inhibit glial cell proliferation. Cultures were used 2 
days after preparation. Dopaminergic neurons in primary cultures were visualized 
by TH-immunohistochemistry (Du et al., 2001) and quantified using a Leitz 
inverted microscope (x 200).  
 
1.4.8.  Immunoblot 
 Western blot analysis was performed on brain extracts from selected 
regions and cell cytoplasmic extracts (Du et al., 2001). Extracts were prepared by 
lysing tissues/cells in a buffer containing 1% Nonidet P-40, 0.1% SDS, 50 mM 
Tris (pH 8.0), 50 mM NaCl, 0.05% deoxycholate, and protease inhibitor (Roche 
Diagnostics Corp., Indianapolis, IN, USA). Proteins were size fractionated on a 4 
– 12% polyacrylamide gradient gel (SDS-NuPAGE) and transferred onto 
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nitrocellulose (Hybond N; Amersham Biosciences, Piscataway, NJ, USA). Blots 
were then probed with polyclonal or monoclonal antibodies (1:500; iNOS, nNOS, 
and caspase-1; Santa Cruz Biotechnology Inc., Santa Cruz, CA, USA), followed 
by a secondary antibody conjugated with horseradish peroxidase (Santa Cruz 
Biotechnology Inc.) and visualized utilizing enhanced chemiluminescence. 
 
1.4.9.  Mitochondrial Isolation and Cytochrome c and AIF Assay 
 Brain mitochondria were prepared from adult C57BL/6 mice. Briefly, brains 
were homogenized in ice-cold buffer (pH 7.4) containing 250 mM mannitol, 75 
mM sucrose, 10 µM K-HEPES and homogenates were centrifuged at 1,000 x g 
for 10 minutes. Supernatants were then centrifuged at 10,000 x g for 15 minutes. 
Pellets were washed three times and immediately used in experiments (Du et al., 
2001). For the in vitro cytochrome c/AIF assay, an aliquot of 12.5 µg brain 
mitochondria (25 µl) was pretreated with CAPE for 5 minutes following challenge 
with 100 µM MPP+ for 30 minutes at 30°C. After centrifugation, the supernatant 
was evaluated by Western blot. 
 To assay in vitro neuronal cytochrome c release, CGN were washed once 
with ice-cold PBS and harvested in 500 µL ice-cold Buffer A (50 mM Tris-HCl, pH 
7.4; 1 mM EDTA; 1 mM DTT; complete EDTA-free Protease Inhibitor Cocktail 
Tablets, Roche Diagnostics Corp.; 250 mM sucrose). The cells were disrupted by 
douncing 10 times with a pestle in a 7-mL Wheaton douncer. After centrifugation 
in a microcentrifuge at 1,000 x g for 10 minutes at 4°C, the supernatants were 
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further centrifuged at 12,000 x g for 40 minutes. The resulting supernatants were 
used for immunoblot analysis. 
 
1.4.10.  Assessment of the Effect of CAPE on MPP+-induced Free Radicals and 
Peroxynitrite Formation 
 To assess superoxide (O ·) production and peroxynitrite in the cultures, 
CGN were treated with MPP+ (70 µM) in the absence or the presence of CAPE 
(2-hour pretreatment) for 24 hours and 48 hours. Neurons were washed twice 
with PBS and 1 mL of PBS containing 10 µg/mL dihydroethidium (DHE; 
Molecular Probes) or 50 µM dihydrorhodamine 123 (DHR; Molecular Probes) was 
then added. After an additional 30 minutes of incubation at 37°C, luminescence 
was measured in a Cytofluor fluorimeter with an excitation wavelength of 485 nm 
(both dyes) and a detection wavelength of 610 nm (DHE) or 530 nm (DHR; Ma et 
al., 2006). 
 
1.4.11.  Statistical Analysis 
 Statistical analysis was performed by linear models. Between groups 
comparisons were conducted by post-hoc tests (F-tests) after model estimation. 
Groups were defined by CAPE dosages (0, 2, 5 and 10 mg/kg p.o.) and 
experiment (Control, C, CA, MPTP/MPP, MPTP/MPP-CA). All data are reported 
as mean ± standard error of the mean. p values less than 0.05 were considered 
significant. All statistical analyses were performed with STATA 11.1 (STATA 
Corp, 2009). 
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1.5.  Results 
 
1.5.1.  MPTP-induced neurotoxicity of midbrain dopaminergic neurons is blocked 
by CAPE 
 C57BL/6 mice were treated with CAPE (2, 5, or 10 mg/kg, p.o.) daily for 7 
days to evaluate a dose response and determine the most effective CAPE 
dosage against MPTP neurotoxicity. Based on these studies, it was observed 
that the doses of 5 mg/kg and 10 mg/kg CAPE significantly preserved DA 
neurons in mice with MPTP exposure. On day 0, mice were administered a 
single CAPE treatment prior to administration of MPTP (4 x 20 mg/kg, i.p.). 
Seven days following the last dose of MPTP, mice that received daily treatments 
of CAPE at either 5 or 10 mg/kg and MPTP showed an increased percentage of 
TH-positive neurons in the SNpc, ranging from 46% of control (no CAPE 
treatment, F(1,32) = 0.89; p = 0.351, Fig 1.8Aa) to 73% (5 mg/kg, F(1,32) = 
34.89, p < 0.001, Fig 1.8Ab) and 92% (10 mg/kg, F(1,32) = 87.73, p < 0.001, Fig 
1.8Ac) of control (Fig 1.8B). CAPE alone (103% of control ± 7.0%) did not alter 
the number of TH-positive neurons significantly (Fig 1.8B). Additionally, HPLC 
analysis of tissues detected 5 µg/mg brain CAPE and 300 g/mL blood CAPE 
from C57BL/6 mice given 10 mg/kg CAPE orally, demonstrating successful 
uptake of the compound and systemic distribution at 1 hour after oral gavage. 
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1.5.2.  CAPE blocks MPTP-induced loss of striatal dopamine 
 Mice that received 10 mg/kg of CAPE had striatal dopamine levels that 
were 32.6% of untreated controls, compared to only 6.6% in the MPTP (alone)-
treated group (F(1,6) = 9.48, p = 0.022; Fig 1.9). 
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Figure 1.8A. CAPE treatment prevented the loss of TH-positive neurons in 
the midbrain following MPTP administration.  
 
C57BL/6 mice were exposed to MPTP and given CAPE treatment as described 
in Experimental Procedures. Whole brains were removed and prepared for 
immunohistochemical analysis of TH-immunoreactivity 7 days after the last 
MPTP exposure. Representative images of coronal sections of mouse brain 
showed that CAPE treatment at 5 mg/kg (c) and 10 mg/kg (d) significantly 
protected the loss of TH-positive neurons induced by MPTP exposure as 
compared to (b) MPTP-exposed animals without CAPE treatment. A wild type 
control without CAPE treatment or MPTP exposure is represented in (a). Scale 
bars: 100 µm.  
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Figure 1.8B. Treatment with CAPE resulted in higher numbers of TH-
positive neurons in midbrain after MPTP exposure. 
 
C57BL/6 mice were administered MPTP and CAPE as described in Experimental 
Procedures. Removal and processing of whole brains was performed at 7 days 
after the last MPTP exposure. A stereological method for counting TH-positive 
neurons and methyl green counterstain was used as previously described by Du 
et al. (2001). CAPE treatment significantly protected animals from MPTP-induced 
dopaminergic cell death. Vehicle, n = 15; 0 mg/kg CAPE (MPTP-alone), n = 14; 2 
mg/kg CAPE, n = 6; 5 mg/kg CAPE, n = 7; 10 mg/kg CAPE, n = 9. ** p < 0.01, *** 
p < 0.001 versus 0 mg/kg CAPE (MPTP-alone). 
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Figure 1.9.  Treatment with 10 mg/kg CAPE decreased the loss of striatal 
dopamine levels in MPTP-exposed mice. 
 
Brains from MPTP-exposed C57BL/6 mice with or without CAPE treatment were 
dissected at 7 days following the last MPTP exposure and prepared for 
dopamine measurement via HPLC analysis as described in Experimental 
Procedures. CAPE treatment resulted in lower reductions in striatal dopamine 
levels as compared to vehicle. Vehicle, n = 15; CAPE, n = 9. * p < 0.05 
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1.5.3.  CAPE does not alter MAO activity and brain MPP+ levels 
 CAPE did not inhibit MAO-B at concentrations as high as 100 µM. By 
comparison, the mixed MAO-A and MAO-B inhibitor, pargyline, inhibited mouse 
brain MAO-B with pI50 values of 8.2 µM.  Moreover, MPP
+ levels in midbrain were 
4.5  1.6 µg/g in untreated or 5.1  0.6 µg/g in CAPE-treated (10 mg/kg) animals 
at 3 hours following MPTP treatment (p = 0.71). With the same treatments, 
midbrain levels of CAPE were 0.22 ± 0.024 µg/g. These data suggest that the 
neuroprotective effect of CAPE is not due to reduced metabolism of MPTP to 
MPP+. 
 
1.5.4.  CAPE blocks MPTP-induced expression of midbrain iNOS and caspase-1 
 Measurements of both iNOS and caspase-1 in midbrain homogenates of 
mice exposed to MPTP were performed (Fig 1.10). At 24 hours following MPTP 
exposure, both iNOS (Fig 1.10b) and caspase-1 (Fig 1.10c) were upregulated, 
but were blocked in the presence of CAPE (Fig 1.10b and 1.10c). In contrast, 
neither MPTP nor CAPE had any effect on nNOS expression in the same 
samples (Fig 1.10a). 
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a. 
 
 
b.      c. 
 
 
Figure. 1.10. CAPE blocked MPTP-induced in vivo expression of iNOS and 
caspase-1. 
 
Immunoblot analyses were performed with polyclonal antibodies against iNOS, 
nNOS, and caspase-1. CAPE blocked MPTP-induced expression of (b) iNOS 
and (c) caspase-1. Note that MPTP and CAPE treatments fail to alter nNOS 
expression in these same samples (a). β-actin was used as an internal loading 
control. “C” represents control group; “M” represents MPTP group; “M-CA” 
represents MPTP + CAPE group. 3 independent experiments (n = 3 per group) 
with similar results were performed. *** p < 0.001 
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1.5.5.  CAPE blocks MPP+ -induced neurotoxicity in both RMN and CGN 
 Neurons were exposed to MPP+ (10 µM for RMN and 70 µM for CGN) in 
the absence or presence of CAPE. CAPE significantly protected RMN (F(1,12) = 
5.04; p = 0.039) (Fig 1.11A and 1.11B) and CGN (F(1,20) = 146.49, p < 0.001) 
(Fig 1.12A and 1.12B) against MPP+ neurotoxicity. Since there is no dopamine 
transporter (DAT) in CGN, our data indicates that CAPE’s inhibition of MPP+-
induced neurotoxicity does not occur via inhibition of DAT activity. Additionally, 
we did not observe MPP+-induced (70 µM) free radical formation in cultured CGN 
(data not shown). 
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Figure 1.11A.  CAPE treatment resulted in reduced RMN cell death induced 
by MPP+ exposure. 
 
RMN cell culture was performed as detailed in Experimental Procedures. RMN 
were pretreated with CAPE (10 µM) for 2 hours followed by MPP+ exposure (10 
µM) for 72 hours. DAB staining with tyrosine hydroxylase antibody was used to 
detect surviving RMN as previously described in Experimental Procedures. 
Representative images of primary cell culture plate fields showed a decrease in 
MPP+-induced RMN cell death in the absence of CAPE, but reduced MPP+-
induced RMN death in the presence of CAPE. Scale bars: 20µm. 
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Figure 1.11B.  CAPE blocked MPP+-induced neurotoxicity of cultured RMN. 
 
RMN cell culture was performed and surviving RMN were detected by using DAB 
staining with tyrosine hydroxylase antibody as previously described in 
Experimental Procedures. RMN were pretreated with CAPE (10 µM) for 2 hours 
followed by MPP+ exposure (10 µM) for 72 hours. A decrease in MPP+-induced 
RMN cell death was observed in CAPE-treated cultures as compared to CAPE-
lacking cultures. Experiments (n = 3 per group) were repeated 3 times with 
similar results. ** p < 0.01 
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Figure 1.12A.  CAPE prevented MPP+-induced cell death of cultured CGN.  
 
CGN were pretreated with CAPE (10 µM) for 2 hours followed by MPP+ exposure 
(70 µM) for a total of 72 hours. Fluorescence staining with fluorescein diacetate 
(green) and propidium idiode (red) was used to visualize surviving CGN (green) 
versus dead CGN (red) as previously described in Experimental Procedures. 
Representative images of primary cell culture plate fields demonstrated a 
decrease of CGN cell death induced by exposure to MPP+ in the presence of 
CAPE. Scale bars: 40µm.  
 
  
59 
 
 
 
 
Figure 1.12B.  MPP+-induced neurotoxicity of CGN is blocked by CAPE. 
 
CGN cell culture was performed and surviving CGN were detected by using a 
fluorescent double-stain technique involving fluorescein diacetate and propidium 
idiode as previously described in Experimental Procedures. CAPE (10 µM) 
pretreatment was applied for 2 hours followed by MPP+ exposure (70 µM) for a 
total of 72 hours. CAPE treatment resulted in a blockade of MPP+-induced CGN 
cell death. Experiments (n = 3 per group) were repeated three times with similar 
results. *** p < 0.001 
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1.5.6.  CAPE blocks MPP+-induced cytochrome c and AIF release 
 Since cytochrome c and AIF were shown to mediate MPP+-induced 
neurotoxicity (Chu et al., 2005), we examined whether MPP+-induced release of 
cytochrome c and AIF was the primary target of CAPE action. A concentration of 
100 µM MPP+ was able to induce cytochrome c and AIF release from brain 
mitochondria; CAPE significantly blocked this induction at 20 µM (Fig 1.13), a 
similar observation that was previously shown with Ca2+-induced cytochrome c 
release in previous studies (Wei et al., 2004). 
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Figure 1.13. CAPE inhibited MPP+-induced cytochrome c and AIF release 
from isolated mouse brain mitochondria. 
 
30 µg of mouse brain mitochondria was exposed to MPP+ (100 µM) for 30 
minutes at 37°C in the absence (M+) or presence of CAPE (M+/CA, 20 µM). 
Experiments (n = 3 brain samples per group) were repeated three times with 
similar results. 
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1.6.  Discussion 
Previous studies from this lab using the MPTP mouse model have 
demonstrated that after 7 days of MPTP exposure, there is a significant decrease 
in the number of TH-positive neurons in the midbrain (Du et al., 2001). The 
present study sought to determine if CAPE confers neuroprotection at this time 
point. Furthermore, previous studies from this lab have also shown that treatment 
with CAPE once daily for 7 days results in prevention of neuronal loss following 
hypoxia-ischemia-induced brain damage (Wei et al., 2004). The present study 
was designed to determine if CAPE treatment once daily for 7 days would 
provide protection in another model of neuronal injury (the MPTP model). Our 
data demonstrate that oral administration of CAPE effectively protects midbrain 
dopaminergic neurons from the toxic effects of MPTP in vivo. Additionally, CAPE 
treatment results in a marked “protective effect” on the depletion of DA in the 
striatum following MPTP administration. Moreover, we have also shown that 
CAPE-induced neuroprotection did not result from alteration of brain MAO activity 
and MPP+ levels.  
In order to investigate whether CAPE could directly protect neurons 
against MPTP/MPP+ neurotoxicity, we used an in vitro system and treated both 
RMN and CGN with MPP+. We have found that CAPE directly blocks MPP+-
induced neuronal death in both RMN and CGN cultures. Given that CGN 
completely lack expression of the DAT and MPP+ induces its neurotoxicity via the 
organic cation transporter 3 (Shang et al., 2003), we suggest that CAPE-induced 
neuroprotection against MPP+ neurotoxicity should not result from inhibiting DAT 
63 
 
function. These results are in agreement with previous studies from this 
laboratory that show CAPE’s neuroprotective effect against 6-OHDA exposure in 
vitro (Noelker et al., 2005; Ma et al., 2006); however, because the 6-OHDA and 
MPP+ models differ in their mechanisms of neurodegeneration and 
neuropathology, it can be posited that CAPE is multifaceted in its neuroprotective 
effects, such that CAPE is effective against neurotoxicity associated with an 
oxidative damage basis (the 6-OHDA model) or neuroinflammation and neuronal 
apoptosis (the MPTP model). 
CAPE has been shown to have anti-inflammatory properties (Wei et al., 
2004) and we demonstrate that CAPE inhibits MPTP-induced iNOS and 
caspase-1 expression in mice. Our data suggest that CAPE could also indirectly 
protect dopaminergic neurons by attenuating MPTP-induced neuroinflammation 
that is detrimental to neurons (Dehmer et al., 2000; Klevenyi et al., 1999; 
Liberatore et al., 1999). 
CAPE has anti-oxidant function that may help protect neurons against 
MPP+-induced neurotoxicity. However, at least in CGN, we did not find that 
CAPE induced neuroprotection from MPP+ neurotoxicity by inhibiting free radical 
generation. Our CAPE data are consistent with other reports indicating the 
neuroprotective efficacy of anti-oxidants on the MPTP animal model; however, 
these data are also contrary to a previous study whereby an antioxidant, 
minocycline, could not directly block MPP+-induced neuronal death, but 
significantly blocked hydrogen peroxide- (H2O2-)induced neuronal death (Du et 
al., 2001, Tikka et al., 2001). Therefore, we sought to investigate whether CAPE 
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provides neuroprotection through other mechanisms. Since cytochrome c /AIF 
release contributes to MPP+ neurotoxicity (Chu et al., 2005) and mitochondria are 
the major target for MPP+, in this study, we investigated if CAPE directly protects 
mitochondrial membrane integrity. We treated isolated brain mitochondria with 
MPP+ and CAPE. 20 µM CAPE significantly blocked MPP+-induced release of 
cytochrome c and AIF from mitochondria, indicating that this compound directly 
protects mitochondria from MPP+ attack. This concentration of CAPE prevents 
the release of cytochrome c either by stimulation due to MPP+ exposure (present 
study) or Ca2+-induced (Wei et al., 2004), further demonstrating that an 
underlying pathway of CAPE neuroprotection involves cytochrome c and the 
mitochondrial membrane. This result indicates that in addition to other anti-
inflammatory and antioxidant functions, CAPE is able to directly block MPP+-
induced neuronal death by protecting the integrity of the mitochondrial 
membrane. 
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CHAPTER 2:  Caffeic Acid Phenethyl Ester Extends Survival of a Mouse Model 
of Amyotrophic Lateral Sclerosis 
 
2.1.  Rationale 
Because the previous study of this dissertation (Chapter 1: Caffeic Acid 
Phenethyl Ester Prevents 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced 
Neurodegeneration) demonstrated the effectiveness of caffeic acid phenethyl 
ester (CAPE) in a neurotoxin-based (1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine, MPTP) mouse model of neurodegeneration, the present 
report sought to validate the use of CAPE for protection against neuronal cell 
degeneration and to verify the compound’s neuroprotective benefit in a 
genetically-engineered animal model of neurodegenerative disease, namely 
amyotrophic lateral sclerosis (ALS).  
This dissertation hypothesizes that despite etiology (environmental versus 
genetic), if two diseases have similar downstream events that are responsible for 
the degeneration of neurons, then the most effective treatment for both diseases 
would need to be beneficial in slowing disease progression by way of targeting 
those shared downstream events. Neurodegenerative diseases share many 
common pathogenic events that lead to the death of neurons, the subsequent 
disease state, and ultimately death. Although the target neurons in each disease 
(dopaminergic neurons in MPTP/PD and motor neurons in ALS) differ, the causal 
mechanisms responsible for progression are similar. Because the underlying 
neuronal death pathways in the MPTP mouse model and PD are comparable to 
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those observed in ALS, the present study was designed to test the effectiveness 
of CAPE against those neuropathologic mechanisms in a mouse model of ALS 
as these analyses have not been examined to date. By using the compound, 
CAPE, that has been shown to host a large array of neuroprotective abilities and 
can target multiple pathogenic pathways, such as those observed in the MPTP 
mouse model of PD discussed in Chapter 1, neurodegeneration and disease 
progression would be slowed, regardless of disease etiology (neurotoxin-based 
versus an underlying genetic mutation). 
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2.2.  Abstract 
 There is currently very limited effective pharmacological treatment for 
amyotrophic lateral sclerosis. Recent evidence suggests that caffeic acid 
phenethyl ester has strong anti-inflammatory, anti-oxidative, and anti-neuronal 
death properties; thus, the present study tested the effects of caffeic acid 
phenethyl ester in mice expressing a mutant superoxide dismutase (SOD1G93A) 
linked to human amyotrophic lateral sclerosis. Administration of caffeic acid 
phenethyl ester after symptom onset significantly increased the lifespan of 
SOD1G93A mice by approximately 2 weeks, nearly doubling post-onset survival. 
Moreover, immunohistochemical analysis detected less activation of microglia 
and astrocytes and higher motor neuron counts at an early symptomatic stage (7 
days following onset) in the spinal cords of SOD1G93A mice given caffeic acid 
phenethyl ester treatment. Additionally, lower levels of phosphorylated p38, a 
mitogen-activated protein kinase that is involved in both inflammation and 
neuronal death, were observed in the spinal cords of SOD1G93A mice treated with 
caffeic acid phenethyl ester for 7 days. These results indicate that caffeic acid 
phenethyl ester may represent a novel and effective therapeutic for the treatment 
of amyotrophic lateral sclerosis and these significant neuroprotective effects 
observed in a commonly used amyotrophic lateral sclerosis mouse model 
validate the therapeutic potential of caffeic acid phenethyl ester for slowing 
disease progression by attenuating the neuroinflammation and motor neuron cell 
death associated with clinical amyotrophic lateral sclerosis pathology. 
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2.3.  Introduction 
2.3.1.  Amyotrophic Lateral Sclerosis 
Amyotrophic lateral sclerosis (ALS) is an incurable, neurodegenerative 
disorder defined by progressive motor neuron loss, leading to paralysis and 
ultimately death within 2 to 5 years after diagnosis. The death of motor neurons 
in the spinal cord results in the atrophy of muscle and eventual paralysis (Tandan 
and Bradley, 1985). ALS incidence is about 2 per 100,000 persons annually in 
the United States (Sejvar et al., 2005) with the majority being sporadic cases and 
5 – 10% familial (Rowland and Shneider, 2001). Because both forms are highly 
similar in clinical course, pathophysiology, and outcome, the underlying 
mechanisms of manifestation and progression are posited to be the same (Bruijn 
et al., 2004). 
The discovery that inheritable (familial) forms of ALS are linked to 
mutations in the Zn/Cu superoxide dismutase (Rosen et al., 1993) (SOD1) led to 
the creation of the SOD1G93A mouse, which is the most extensively-studied 
animal model of ALS (Gurney et al., 1994; Alexander et al., 2004). The model 
exhibits the major ALS hallmarks, including motor neuron pathology leading to 
progressive paralysis (Gurney et al., 1994; Alexander et al., 2004). Use of this 
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model uncovered an array of processes involved in ALS onset and progression, 
including glutamate excitotoxicity, oxidative damage, glial cell activation, 
neuroinflammation, mitochondrial dysfunction, and aberrant protein folding and 
axonal transport (Rowland and Shneider, 2001; Rothstein, 2009). 
 
 
 
Turner and Talbot, 2008 
Figure 2.1 Discovered mutations in the SOD1 human gene. 
 
These mutations were observed in over 13 families with familial forms of ALS 
(fALS; Rosen et al., 1993). At position 93, the SOD1G93A mice have a single 
glycine (G) to alanine (A) mutation that is required for the animal to develop 
disease (Gurney et al., 1994). To date, there are over 150 mutations found in the 
Cu, Zn-SOD1 gene (Rosen et al., 1993), which have led to the development of 
mouse models of ALS. 
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2.3.2.  Treatments for ALS 
Because multiple neuronal death pathways are implicated in disease 
development and maintenance, the pathophysiological processes in humans 
may not be addressable by targeting (inactivating) a single neurodegenerative 
process; rather, a multi-target approach may be required to effectively control 
disease progression (Rothstein, 2009). Additionally, as no pre-symptomatic 
predictors, diagnostic tests, or biomarkers for ALS currently exist, treatment can 
only be applied after symptom onset (Rowland and Shneider, 2001).  
A large number of pharmacologic therapies used in both clinical trials and 
stringent testing at the ALS Therapy Development Institute (ALS-TDI; Scott et al., 
2008) have been unsuccessful in providing protection against the 
neurodegeneration of motor neurons observed in ALS (Scott et al., 2008). These 
failures at the pre-clinical or clinical stage may be attributed to the treatment’s 
inability to target more than one neuronal death pathway, resulting in an 
incomplete or ineffective blocking of motor neuron cell loss and ALS disease 
progression. 
 
2.3.2.1.  Riluzole (Rilutek®) 
Because excitotoxicity is posited to be involved in the motor neuron death 
observed in ALS, interest in anti-glutamatergic agents for ALS drug development 
ensued. To date, the only FDA-approved treatment for the slowing of ALS 
progression and extending of survival is riluzole (Rilutek®; Gurney et al., 1996, 
1998). Riluzole’s mode of action was found to involve the inhibition of the release 
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of glutamate release at the nerve terminal (Martin et al., 1993). One proposed 
mechanism of inhibition is thought to be related to riluzole functioning as a 
noncompetitive antagonist at glutamate receptors, specifically of the N-methyl-D-
aspartate (NMDA) type (Malgouris et al., 1994). Early treatment with riluzole in 
SOD1G93A mice with disease onset demonstrated prolonged survival and 
preserved motor performance, as assessed by wheel running behavior, 
suggesting that riluzole may be beneficial as a treatment for early stages of ALS 
(Gurney et al., 1998). In ex vivo studies, riluzole exhibited neuroprotection 
against chronic glutamate-induced neuronal death in spinal cord explants 
(Rothstein and Kuncl, 1995). Shifted survival times were also observed with 
treatments with other anti-glutamatergic agents, such as gabapentin (Gurney et 
al., 1996) and memantine (Wang and Zhang, 2005). Despite its modest effect on 
patient life extension of 2 – 5 months (Scott et al., 2008), riluzole is currently the 
only available treatment for the ALS patient.  
 
2.3.3.  Caffeic Acid Phenethyl Ester and Neuroprotection 
The use of a naturally-derived compound, caffeic acid phenethyl ester 
(CAPE), for treating an animal model of neurodegenerative disease and 
examination of the mechanisms underlying its neuroprotective ability were 
previously investigated by this laboratory (Ma et al., 2006; Wei et al., 2008). 
CAPE has numerous potentially beneficial properties, including 
immunomodulatory, anti-oxidant, and anti-inflammatory activities (Su et al., 1991, 
1994; Grunberger et al., 1988), which this laboratory and collaborators has 
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previously found to protect against multiple cell death processes in vitro in a 6-
hydroxydopamine-exposed cell culture model of neuronal death (Noelker et al., 
2005; Ma et al., 2006; Wei et al., 2008) and in vivo against hypoxia-ischemia 
injury in neonatal rats (Wei et al., 2004). For a further review of CAPE, please 
see Section 1.3.4. Caffeic Acid Phenethyl Ester located in Chapter 1. 
 
2.3.4.  The SOD1G93A Mouse Model of ALS 
 When discoveries of SOD1 mutations in familial ALS were made, focus 
was quickly placed on the development of transgenic mouse models of ALS, 
such as the SOD1G93A mouse. This transgenic mouse model of ALS carries a 
transgenic construct with a glycine (G) to alanine (A) mutation at position 93 and 
is driven by the endogenous wild type mouse SOD1 promoter (Gurney et al., 
1994). Thus, these mice carry genes for both endogenous wild type mouse 
SOD1 and the mutated human G93A transgene.  
At around 90 days of age, the SOD1G93A mouse develops hind-limb 
weakness, which progresses to hind-limb hyperreflexia and followed by paralysis 
and death (Gurney et al., 1994). Spinal cord pathology demonstrates motor 
neuron death initially detected at the lumbar level and becoming widespread as 
the disease progresses. In addition to motor neuron degeneration in the spinal 
cord, astrocytosis and microgliosis is observed (Hall et al., 1998). The SOD1G93A 
mouse is the most widely used model for ALS and is also the most well-
characterized. It is able to exhibit the putative neurodegenerative mechanisms 
associated with ALS, including glutamate-mediated excitotoxicity, mitochondrial 
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dysfunction, oxidative damage, neuroinflammation, apoptosis, and ER stress 
(See Table 2.1) in the spinal cord. However, over a decade after development of 
the SOD1G93A mouse, the reasons and mechanisms underlying the selectivity of 
mutant SOD1 for motor neurons is not yet known. The current prevailing theory is 
that the G → A mutation at position 93 confers an unknown “gain of function” 
property (Gurney et al., 1994). 
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2.3.5.  Comparison of the Mechanisms of the ALS and MPTP Mouse Models 
 Below is a table listing the major mechanisms involved in neuronal death 
in both the MPTP mouse model of PD and the SOD1G93A mouse model of ALS. 
 
Table 2.1.  Mechanism Comparison of the ALS and MPTP Mouse Models 
Mechanism MPTP mouse model  SOD1G93A mouse model  
 
mitochondrial dysfunction 
inhibition of 
mitochondrial Complex I 
(Kindt et al., 1987) 
defective mitochondrial 
respiration (Mattiazzi et 
al., 2002) 
 
oxidative stress 
increased lipid 
peroxidation and 
decreased glutathione 
levels in midbrain (Hung 
and Lee, 1998) 
 
increased nitrotyrosine 
levels in spinal cord 
(Wootz et al., 2004) 
 
neuroinflammation 
increased microglia 
activation and IL-1β and 
iNOS levels (Wu et al., 
2002) 
increased microglia and 
astrocyte activation and 
ICAM-1 levels (Alexianu 
et al., 2001) 
 
 
excitotoxicity 
glutamate-induced 
damage to dopaminergic 
somata in substantia 
nigra (Loschmann et al., 
1994) 
neuron death due to 
elevated glutamate levels 
caused by loss of glial 
glutamate transporters 
(Rothstein et al., 1996) 
 
protein aggregation 
upregulation of synuclein 
mRNA and protein in DA 
neurons in SN (Vila et 
al., 2000) 
mutant-mediated toxicity 
due to aggregation of 
cellular proteins and 
mutant SOD1 (Bruijn et 
al., 1998) 
 
programmed cell death 
exposure to low MPP+ 
concentrations results in 
apoptosis (Du et al., 
1997) 
activation of 
mitochondrial-dependent 
apoptotic proteins 
(Guegan et al., 2001) 
 
 
ER stress 
activation of unfolded 
protein response (UPR) 
due to protein 
accumulation in ER 
(Sado et al., 2009) 
increased activation of 
caspase-12 and UPR 
(Nagata et al., 2007) 
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 Because the SOD1G93A mouse model of ALS share and its associated 
human disease share common downstream pathogenic pathways with the MPTP 
mouse model of PD, CAPE treatment in the former should be neuroprotective 
against the death of motor neurons in the same manner as the neuroprotection 
observed in the latter. It is also demonstrated that regardless of disease etiology 
(neurotoxin-induced versus genetic mutation) and neuron type (dopaminergic 
versus motor), the shared endpoint is neuronal death. 
The present study for Chapter 2 of the dissertation determined the cellular 
and biochemical responses to CAPE and evaluated its effectiveness against 
neurodegeneration in the SOD1G93A mouse using clinically-relevant dosing 
parameters to further validate the use of CAPE for protection against the 
neuronal cell death occurring in the established disease state. 
 
2.4.  Experimental Procedures 
 
2.4.1.  Animals 
 All animal procedures were conducted in compliance with the protocols 
approved and authorized by the Institutional Animal Care and Use Committee at 
the Indiana University School of Medicine. 
 
2.4.1.1.  The SOD1G93A mouse model of ALS 
 Male and female transgenic mice overexpressing the human SOD1-G93A 
mutation (SOD1G93A mice) were maintained in-house as hemizygotes on a B6SJL 
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background by crossing B6SJL-Tg(SOD1-G93A)1Gur/J males (stock #JR2726; 
The Jackson Laboratory, Bar Harbor, ME, USA; Gurney et al., 1994) with wild 
type control B6SJLF1/J females (stock #100012; The Jackson Laboratory). Mice 
carrying the SOD1G93A mutation were identified by performing PCR on tail tissue-
derived DNA using a protocol provided by The Jackson Laboratory. 
 
2.4.1.2.  Behavioral Assessment of Animals 
 Beginning at 90 days of age, male and female SOD1G93A mice were 
randomly assigned to either “vehicle” or “CAPE” groups and tested twice a week 
on a Rotarod apparatus (ENV-575M; Med Associates, Inc., St. Albans, VT, USA) 
with up to 3 trials per day. Disease onset was determined when the animal 
became unable to remain on the apparatus for 10 minutes at a speed of 15 rpm. 
Additionally, Rotarod performance was tested the day after the animal was 
unable to remain on the apparatus for the defined parameters in order to further 
verify disease onset. End stage (surrogate death time point) was defined when 
the animal could not right itself within 20 seconds of being gently rolled on its 
side. Mice were monitored every morning for morbidity and mortality and every 
afternoon for the righting reaction.  
 
2.4.1.3.  Animal Treatment Protocol 
 CAPE (Sigma-Aldrich Corp., St. Louis, MO, USA) was dissolved in 
HotRod Formulation (Pharmatek, San Diego, CA, USA) vehicle and orally 
administered at a single dose of 2.5, 10, or 40 mg/kg, once daily, for optimal 
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dose determination experiments and a single dose of 10 mg/kg, once daily, for 
subsequent immunohistochemical and biochemical experiments. Animals in the 
vehicle group (HotRod alone) were given an equivalent volume according to 
body weight. Mice received one daily dose of CAPE or vehicle until a humane 
endpoint near death (survival studies) or for 3 or 7 days after disease onset 
(biochemical and immunohistochemical studies).  
 
 
Figure 2.2. Diagram of the Animal Treatment Protocol for the current study. 
 
 
2.4.2.  Immunoblot 
 Western blot analysis was performed on tissue lysates (15 µg/well) as 
previously described (Wei et al., 2004) after 7 days of treatment with CAPE or 
vehicle. Spinal cord samples were homogenized in radio-immunoprecipitation 
assay (RIPA) buffer containing 1% Nonidet P-40, 0.1% SDS, 50 mM Tris (pH 
8.0), 50 mM NaCl, 0.05% deoxycholate, and protease inhibitor (Roche 
Diagnostics Corp., Indianapolis, IN, USA). Proteins were size-fractionated (SDS-
NuPAGE) on a 4 – 12% polyacrylamide gradient gel and transferred onto 
nitrocellulose (Hybond N; Amersham Biosciences, Piscataway, NJ, USA). Blots 
were incubated with rabbit polyclonal primary antibody specific for 
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phosphorylated-p38 (1:1000; Millipore, Temecula, CA, USA) followed by 
horseradish peroxidase-conjugated secondary antibody (Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA), visualized via enhanced 
chemiluminescence (Amersham Biosciences, Piscataway, NJ, USA), and 
quantitated by densitometric analysis (ImageJ, http://rsbweb.nih.gov/ij/).  
 
2.4.3.  Immunohistochemistry 
 Following 7 days of treatment with CAPE or vehicle, mice were 
anesthetized by isofluorane inhalation and perfusion-fixed with 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). Spinal cords were 
removed, fixed in 4% paraformaldehyde overnight at 4°C, and prepared for 
paraffin embedding. Samples were serially sectioned (15 µm) through the 
enlargement of the lumbar spinal cord and immunostained with mouse 
monoclonal primary antibody against microtubule-associated protein 2 (1:1000, 
MAP2; Millipore), mouse monoclonal antibody against glial fibrillary acidic protein 
(1:1000, GFAP; Millipore), or rabbit polyclonal antibody against ionized calcium 
binding adaptor molecule 1 (1:500, Iba-1; Wako Chemicals USA, Inc., Richmond, 
VA, USA; Ito et al., 2001; Sasaki et al., 2001; Voskuhl et al., 2009) followed by 
incubation with biotinylated secondary antibodies (Sigma-Aldrich Corp.). 
Visualization of the immunoreactions was performed using an avidin-biotin 
complex kit (Vector Laboratories Inc., Burlingame, CA, USA) with 3,3’-
diaminobenzene tetrahydrochloride dehydrate as the chromogen (Sigma-Aldrich 
Corp.). Immunohistochemical negative control sections were treated with the 
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same protocol except for incubation with primary antibody and no specific 
staining was seen. Sections used for motor neuron counting were first observed 
for defined MAP2-immunoreactive neuronal processes then counterstained using 
Mayer’s hematoxylin (Sigma-Aldrich Corp.) prior to mounting. Large motor 
neurons were counted in the ventral horn of lumbar spinal cord by using a light 
microscope with an x40 objective (Nikon, Japan) and were identified by a 
basophilic cellular outline (containing Nissl substance) and a prominent nucleolus 
(Grossman et al., 2001; Sato et al., 2003). A total of 6 – 8 sections per animal 
through the lumbar area of the spinal cord were counted and reported as number 
of motor neurons per section as previously described (Dodge et al., 2008). For 
sections immunostained with Iba-1, as described previously (Ito et al., 2001; 
Sasaki et al., 2001; Voskuhl et al., 2009), activated microglia were characterized 
by a rounded cell body with short processes versus a resting or “ramified” 
morphology. 
 
2.4.4.  Statistical Analysis 
 All data are expressed as mean ± standard error of the mean (SEM). One-
way analysis of variance (ANOVA) was used for statistical analyses and 
comparisons.  
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2.5.  Results 
 
2.5.1.  Post-onset CAPE treatment of SOD1G93A mice significantly diminished 
symptomatic progression and extended life span 
 The potential for orally administered CAPE to attenuate progression of 
established disease-like symptoms was assessed in the SOD1G93A-ALS mouse 
model. Disease onset was determined via bi-weekly Rotarod monitoring of motor 
function and limb strength. Initial experiments were performed to determine an 
optimal dose whereby CAPE offers benefit to the SOD1G93A mouse. CAPE-
treated animals at all doses (2.5, 10, and 40 mg/kg) showed significant extension 
of survival time (group means: 26.6 ± 2.8 days, 28.4 ± 2.0 days, and 26.1 ± 3.6 
days, respectively) when compared to vehicle-treated mice (14.3 ± 0.63 days, p < 
0.01; Fig 2.3A), resulting in lengthened lifespan (group means: 132.1 ± 9.4 days, 
138.6 ± 11.1 days, and 137.0 ± 14.3 days, respectively; Fig 2.3B) as compared 
to vehicle (122.1 ± 2.0 days, p < 0.01).  
HPLC analysis of brain homogenate and whole blood at 1 hour after oral 
gavage (10 mg/kg CAPE) detected 5 µg CAPE/100 mg brain and 300 µg CAPE/1 
mL blood, demonstrating successful uptake by CNS tissues as well as systemic 
distribution. Additionally, HPLC testing of spinal cord tissue at 1 hour post-
gavage revealed detection of 81 ng/g tissue for wild type control and 1,026 ng/g 
tissue for SOD1G93A mouse with disease onset, suggesting that a compromised 
blood brain barrier (Garbuzova-Davis et al., 2007) allowed for increased spinal 
cord uptake of CAPE in symptomatic SOD1G93A mice. 
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Figure 2.3A.  CAPE treatment at increasing doses significantly elongated 
post-onset survival with disease onset. 
 
Male and female SOD1G93A mice with disease onset were administered CAPE 
(2.5, 10, or 40 mg/kg) or vehicle until the death endpoint. The number of days 
between disease onset and a humane endpoint near death were measured and 
reported as probability of duration. Mice with disease onset who were treated 
with CAPE at any dose (2.5 mg/kg, n = 14; 10 mg/kg, n = 14; 40 mg/kg, n = 11) 
had a significant extension of survival time as compared to SOD1G93A mice 
without CAPE (n = 12).  
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Figure 2.3B.  CAPE treatment at increasing doses significantly lengthened 
lifespan of SOD1G93A mice with disease onset. 
 
Male and female SOD1G93A mice with disease onset were treated with CAPE 
(2.5, 10, or 40 mg/kg) or vehicle until the death endpoint. The number of days 
between birth and a humane endpoint near death were measured and reported 
as lifespan. Mice with disease onset who were treated with CAPE at any dose 
(2.5 mg/kg, n = 14; 10 mg/kg, n = 14; 40 mg/kg, n = 11) had a significant lifespan 
extension when compared to SOD1G93A mice with no CAPE treatment (n = 12). 
Extended post-onset survival times of all CAPE-treated mice (2.5, 10, and 40 
mg/kg doses) resulted in the marked lengthening of lifespan relative to vehicle 
mice.  
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2.5.2.  Daily oral CAPE treatment at a dose of 10 mg/kg is optimal for 
significantly decreasing disease progression and lengthening life span of 
symptomatic SOD1G93A mice 
 For additional subsequent experiments (Fig 2.4), the 10 mg/kg CAPE 
dose was selected as it was observed that the response of SOD1G93A mice to 
CAPE treatment had reached a plateau at 10 mg/kg such that there was no 
significant increase in survival time or lifespan at the 40 mg/kg dose as compared 
to 10 mg/kg. There was no difference in age of disease onset between CAPE (10 
mg/kg) and vehicle groups (group means: 111.3 ± 2.6 days and 107.3 ± 2.6 
days, respectively; data not shown). In accordance with initial dose response 
studies shown in Fig 2.3, additional studies (Fig 2.4) with daily administration of 
10 mg/kg CAPE resulted in markedly increased time of post-onset disease 
duration (29.3 ± 2.0 days, p < 0.01; Fig 2.4A) compared to vehicle-treated 
animals (14.6 ± 0.68 days). This result was qualitatively reflected in total lifespan 
(Fig 2.4B), with CAPE-treated SOD1G93A mice surviving 140.6 ± 2.4 days 
compared to 121.9 ± 2.2 days in the vehicle group (p < 0.01). 
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Figure 2.4A.  CAPE (10 mg/kg) treatment lengthened disease duration of 
SOD1G93A mice with disease onset. 
 
Male and female SOD1G93A mice with disease onset were given CAPE (10 
mg/kg) or vehicle until a humane endpoint near death. The length of time 
between onset and the death endpoint was examined, reported as post-onset 
time, and measured in days of post-onset time. Mice treated with CAPE (n = 13) 
had longer post-onset survival time compared to vehicle-treated mice (n = 11). 
The calculated averages (± SEM) of survival post-onset of CAPE-treated mice 
were significantly greater than the vehicle group. Statistical analysis was 
performed using one-way ANOVA. **, p < 0.01.  
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Figure 2.4B.  CAPE (10 mg/kg) treatment of symptomatic SOD1G93A mice 
resulted in elongated lifespans. 
 
Symptomatic male and female SOD1G93A mice were treated with CAPE (10 
mg/kg, n = 13) or vehicle (n = 11) until a humane endpoint near death. The 
length of time between birth and the death endpoint was examined, reported as 
lifespan, and measured in days of lifespan. The effect of CAPE treatment at 
onset was sufficiently robust to produce a significantly greater total lifespan 
extension. Statistical analysis was performed using one-way ANOVA. **, p < 
0.01.  
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2.5.3.  A greater number of motor neurons in the lumbar spinal cord survived with 
CAPE treatment 
 It was determined whether the protective effect of CAPE correlated with 
prevention of motor neuron loss. Changes in motor neuron density at 7 days 
post-onset were evaluated in cross-sections of lumbar spinal cords of the 
SOD1G93A study mice (Fig 2.5A). Vehicle-treated mice exhibited a significant (p < 
0.01) loss of motor neurons in the ventral horn of the spinal cord lumbar region 
as compared to age-matched, wild type littermates (group means: 8.48 ± 0.51 
and 20.2 ± 0.48, respectively; Fig 2.5B). Motor neuron loss was prevented at this 
time point by CAPE treatment (18.1 ± 1.4, p < 0.01 vs. vehicle) and was not 
significantly lower than age-matched, wild type mice (Fig 2.5B). Additionally, 
MAP2-immunoreactive neuronal processes were observed and clearly defined 
throughout spinal cord sections obtained from wild type and CAPE-treated mice. 
In contrast, there was very little to no presence of MAP2-positive axons and 
dendrites in vehicle-treated SOD1G93A mice spinal cord (Fig 2.5A). 
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Figure 2.5A.  More motor neurons were present in lumbar spinal cords of 
SOD1G93A mice treated with CAPE upon disease onset. 
 
Symptomatic SOD1G93A mice were treated with or without CAPE (10 mg/kg) for 7 
days. Motor neurons in the lumbar spinal cord region were visualized by 
immunohistochemical staining with antibodies to MAP2 and counterstained with 
hematoxylin to visualize total nuclei as described in the Experimental Procedures 
section. Representative immunohistochemical images of lumbar spinal cord 
sections demonstrated an increase in the presence of MAP2-positive neurons in 
mice treated with CAPE compared to vehicle. Scale bars: 100 µm. 
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Figure 2.5B.  Higher numbers of motor neurons were observed in lumbar 
spinal cords of SOD1G93A mice treated with CAPE. 
 
SOD1G93A mice with disease onset were treated with or without CAPE (10 mg/kg) 
for 7 days. Digitized images covering the entire cross-sectional area from 6 – 8 
lumbar spinal regions from each mouse in the study were quantitated for 
staining. CAPE treatment resulted in a greater number of motor neurons in 
lumbar spinal cord from symptomatic SOD1G93A mice as compared to vehicle. 
Data for experimental groups are presented as averages (+ SEM) of 3 
independent tests consisting of 3 animals per group for each test. Data for wild 
type controls were generated from 4 mice. Statistical analyses were performed 
using one-way ANOVA. **, p < 0.01. 
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2.5.4.  Administration of CAPE had no effect on endogenous mouse SOD1wild type 
and mutant human SOD1G93A expression in spinal cords of SOD1G93A mice 
 Because the transgene copy number (the copies of the transgene with the 
G → A at position 93, human mutant form of SOD1) has been shown to affect 
survival of the SOD1G93A mouse (Alexander et al., 2004b), immunoblot analyses 
of SOD1 expression were performed on spinal cord homogenates after 7 days of 
CAPE treatment (Fig 2.6A). Quantitative measurement of band densities 
revealed that levels of both wild type endogenous mouse SOD1 (mSOD1WT) and 
mutated human SOD1 (hSOD1G93A) expression showed no differences with or 
without 7-day CAPE treatment (Fig 2.6B). It is important to note that “wild 
type/WT” mice express wild type endogenous mouse SOD1 (mSOD1WT) but do 
not carry the mutated human SOD1 (hSOD1G93A) transgene; “vehicle” and 
“CAPE” mice are the experimentally-treated SOD1G93A transgenic mice that 
express wild type endogenous mouse SOD1 (mSOD1WT) as well as the mutated 
human SOD1 (hSOD1G93A) transgene. There were no differences in expression 
of actin, which served as an internal loading control for endogenous mouse 
SOD1 (mSOD1WT). Additionally, no differences were observed in endogenous 
mouse SOD1 (mSOD1WT) levels, which served as an internal control for mutated 
human SOD1 (hSOD1G93A) expression. 
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A. 
 
B.
 
 
Figure 2.6. CAPE treatment did not affect endogenous mouse wild type 
SOD1 and mutated human SOD1 transgene expression in spinal cord. 
 
Wild type control (“WT”) and SOD1G93A mice (“vehicle” and “CAPE”) spinal cords 
were prepared as detailed in Experimental Procedures. Levels of actin were 
unchanged and used as an internal loading control for endogenous mouse wild 
type SOD1 (“mSOD1WT”). There was no difference in mSOD1WT levels, which 
was the loading control for mutated human SOD1 (“hSOD1G93A”). After 7 days of 
CAPE treatment, there was no change in expression of either endogenous 
mouse wild type SOD1 or human SOD1 carrying the G93A mutation in 
symptomatic SOD1G93A mice. n = 3 per group, ***p < 0.005. 
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2.5.5.  Daily CAPE treatment decreased phosphorylation of p38 MAP kinase in 
spinal cords of SOD1G93A mice 
 Since motor neuron loss occurs, at least in part, through the action of 
neighboring activated inflammatory cells (Boillee et al., 2006a) and CAPE has 
demonstrated anti-inflammatory and anti-cell death properties (Wei et al., 2004), 
the effect of CAPE administration on a molecular pathway associated with 
inflammation and cell death was examined. The levels of activated 
phosphorylated p38 protein in spinal cords were evaluated at 3 days (Fig 2.7A) 
and 7 days (Fig 2.7B) following disease onset and with or without CAPE 
administration during that time period. As demonstrated in other reports with this 
ALS mouse model (Hu et al., 2003; Dewil et al., 2007), the phosphorylation 
status of p38 was elevated in SOD1G93A after disease-like symptoms manifested 
at both 3 days (0.37 ± 0.11, p < 0.05 vs. wild type; Fig 2.7Ab) and 7 days post-
onset (0.572 ± 0.11, p < 0.01 vs. wild type; Fig 2.7Bb). Conversely, levels of 
phospho-p38 protein in the spinal cords were significantly reduced with CAPE 
treatment for 3 days (0.20 ± 0.058, p < 0.05 vs. vehicle; Fig 2.7Ab) and for 7 days 
(0.248 ± 0.057, p < 0.05 vs. vehicle; Fig 2.7Bb) as compared to the vehicle 
groups. However, these phospho-p38 levels observed in CAPE-treated animals 
were still higher than age-matched, wild type controls at 7 days (0.0457 + 
0.000010, p < 0.05 vs. CAPE group; Fig 2.7Bb). 
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a. 
 
 
b. 
 
 
Figure 2.7A. Reduced phosphorylation of p38 in spinal cords of SOD1G93A 
mice with disease onset was observed after 3 days of CAPE treatment. 
 
SOD1G93A mice with onset received 10 mg/kg CAPE or vehicle for 3 days and 
spinal cords were prepared for immunoblot analysis as detailed in Experimental 
Procedures. (a) Representative Western blots and (b) quantitation of band 
density showed reduced p38 phosphorylation in spinal cords of symptomatic 
SOD1G93A mice given 3-day CAPE treatment versus vehicle. Total p38 
expression remained unchanged and served as an internal loading control. 
Values are the mean density ± SEM. One-way ANOVA was used for statistical 
analysis. *, p < 0.05; n = 2, WT; n = 3, vehicle; n = 3 , CAPE. 
  
* 
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a. 
 
 
 
b. 
 
 
Figure 2.7B. Decreased levels of phospho-p38 in spinal cords of 
symptomatic SOD1G93A mice were observed after 7 days of CAPE treatment. 
 
Symptomatic SOD1G93A mice were given CAPE (10 mg/kg) or vehicle for 7 days 
and spinal cords were harvested for Western blotting as described in 
Experimental Procedures. (a) Representative immunoblots and (b) densitometric 
quantitation demonstrated reduced phosphorylated p38 expression with CAPE 
treatment as compared to vehicle-treated animals. Unchanged total p38 levels 
served as an internal loading control. Values represent the mean density ± SEM. 
Statistical analysis was performed using one-way ANOVA. *, p < 0.05; **, p < 
0.01; n = 3 , WT; n = 3, vehicle; n = 4 , CAPE. 
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2.5.6.  A reduction in astroglial activation was observed in the spinal cords of 
symptomatic SOD1G93A mice treated with CAPE 
 The neuroprotective effect of CAPE was confirmed at the cellular level by 
determining the astroglia activation state in the spinal cord. Astroglial cell 
induction within the lumbar spinal cords of SOD1G93A mice was assessed by 
immunohistochemical analyses (Fig 2.8A). Immunostaining for GFAP expression 
in the lumbar spinal cord paraffin-embedded sections demonstrated decreased 
levels of GFAP immunoreactivity with CAPE treatment compared to vehicle-
treated controls (Fig 2.8A). For comparison, wild type controls were also 
analyzed for astroglial activation and showed very little to no GFAP 
immunoreactivity (representative slide not shown). The density per cross-
sectional area of GFAP-positive astrocytes was elevated by over 50-fold in the 
vehicle-treated group (125.6 ± 9.1, p < 0.01 vs. wild type; Fig 2.8B) as compared 
to wild type control mice (2.25 ± 0.85, Fig 2.8B). In contrast, CAPE-treated 
SOD1G93A mice exhibited a markedly lower number of GFAP-positive astrocytes 
(20.3 ± 3.1, p < 0.01) compared to the vehicle group (Fig 2.8B). However, the 
number of GFAP-positive astrocytes in CAPE-treated mice was still significantly 
higher (p < 0.01) compared to wild type controls (Fig 2.8B).  
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Figure 2.8A. CAPE reduced the presence of activated astrocytes in lumbar 
spinal cords of symptomatic SOD1G93A mice. 
 
Mice were treated for 7 days with CAPE or vehicle and lumbar spinal cords were 
removed for analysis and processed as previously described in Experimental 
Procedures. For comparison, wild type control mice were also analyzed. 
Representative immunohistochemical images of lumbar spinal cord sections 
demonstrated a decrease in the presence of GFAP-positive astrocytes in mice 
treated with CAPE compared to vehicle. Wild type controls showed very little to 
no GFAP-positive staining (representative section not shown). Scale bars: 50 
µm. 
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Figure 2.8B. CAPE reduced the number of activated astrocytes in lumbar 
spinal cords of symptomatic SOD1G93A mouse. 
 
For 7 days, mice were given CAPE or vehicle. Lumbar spinal cord removal and 
processing were performed as previously described in Experimental Procedures. 
Wild type control mice were also analyzed. Digitized images of stained sections 
were quantitated and demonstrated lower numbers of GFAP-positive cells in the 
spinal cord with CAPE treatment as compared to vehicle. Values represent the 
mean ± SEM. Statistical analysis was performed using one-way ANOVA. **, p < 
0.01; n = 4, WT; n = 8, vehicle, n = 9, CAPE. 
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2.5.7.  Administration of CAPE to SOD1G93A mice with disease onset decreased 
CD11b expression in spinal cords 
 For further examination of glial activation in spinal cords after CAPE 
treatment, expression of a marker of activated microglia, CD11b, which is 
induced by inflammation (Boillee et al., 2006), was detected via Western blotting 
at 3 days (Fig 2.9A) and 7 days (Fig 2.9B) after SOD1G93A mice were given 10 
mg/kg CAPE. At 3 days post-CAPE treatment of symptomatic mice, 
representative immunoblots (Fig 2.9Aa) and subsequent band density 
measurements (Fig 2.9Ab) revealed no differences in CD11b expression in all 
groups (group averages ± SEM: 0.266 ± 0.065 for wild type, n = 4 ; 0.276 ± 0.046 
for vehicle, n = 3; 0.298 ± 0.0074 for CAPE, n = 3). However, after 7 days of 
post-onset CAPE treatment, representative immunoblot (Fig 2.9Ba) and band 
density measurements (Fig 2.9Bb) showed there was a significant increase in 
CD11b expression in the spinal cord of vehicle mice (0.669 ± 0.057 for vehicle, n 
= 3, *** p < 0.005 versus wild type and CAPE) when compared to CAPE-treated 
animals (0.248 ± 0.036, n = 3), whose CD11b expression was found to be at a 
similar level to wild type mice (0.288 ± 0.024 , n = 3) after 7 days.  
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a. 
 
 
 
 
b. 
 
 
 
Figure 2.9A. No difference in CD11b-immunoreactivity was observed at 3 
days post-onset with CAPE treatment. 
 
Lumbar spinal cords were removed and processed at 3 days post-onset for 
Western blot as described in Experimental Procedures. Unchanged actin in all 
groups served as an internal loading control. (a) The representative immunoblots 
and (b) band densities that were measured showed no change in spinal cord 
CD11b expression after 3 days of disease onset diagnosis with or without 10 
mg/kg CAPE treatment. WT (wild type), n = 4; vehicle, n = 3; CAPE, n = 3. 
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a. 
 
 
 
 
 
b. 
 
 
Figure 2.9B. 7-day treatment with CAPE reduced expression of CD11b in 
spinal cords of symptomatic SOD1G93A mice. 
 
Spinal cords were removed for CD11b immunoblot as described in Experimental 
Procedures. Actin expression was unchanged in all groups and served as an 
internal loading control. (a) Representative immunoblots and (b) band 
quantitation demonstrated a decrease in spinal cord CD11b expression after 7-
day CAPE treatment as compared to vehicle. WT (wild type), n = 3; vehicle, n = 
3; CAPE, n = 3. *** p < 0.005. 
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2.5.8.  SOD1G93A mice with disease onset and treated with CAPE demonstrated 
reduced microglial activation in lumbar spinal cords 
 CAPE’s neuroprotection was further observed at the cellular level by 
examining the presence of activation of microglia in the spinal cord. Because 
CD11b is not specific to microglia, immunohistochemical analysis with a 
microglia-specific marker, Iba-1 (Ito et al., 2001) was used. Microglial activation 
closely paralleled astrocyte GFAP-immunoreactivity (See previous Fig 2.8A and 
2.8B) in lumbar spinal cords with or without CAPE treatment for 7 days (Fig 
2.10A). 
 The number of activated microglia in lumbar spinal cords of SOD1G93A 
mice was markedly decreased by CAPE treatment (44.8 ± 1.8, p < 0.01 vs. 
vehicle) in comparison to animals without CAPE (84.5 ± 4.3) as confirmed by 
immunostaining with Iba-1 (Fig 2.10B). For comparison, age-matched, wild type 
littermates given CAPE for 7 days exhibited no activated microglia with Iba-1 
immunoreactivity in the spinal cord lumbar area (representative slide not shown). 
As observed with the number of GFAP-positive cells in lumbar spinal cord, the 
number of Iba-1-positive cells in CAPE-treated mice was still significantly higher 
compared to wild type controls (0.00 ± 0.0; Fig 2.10B). 
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Figure 2.10A. CAPE reduced the presence of activated microglia in lumbar 
spinal cords of symptomatic SOD1G93A mice. 
 
Lumbar spinal cords of mice were analyzed for activated microglia by 
immunohistochemical staining with antibodies to Iba-1 at post-onset day 7 of the 
study. Representative sections of spinal cord revealed diminished 
immunostaining of activated microglia in the lumbar area in mice given CAPE 
versus their vehicle counterparts. Wild type controls did not show any Iba-1-
positive staining (representative section not shown). Scale bars: 50 µm. 
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Figure 2.10B. CAPE reduced the number of activated microglia in lumbar 
spinal cords of symptomatic SOD1G93A mice. 
 
Lumbar spinal cords of mice were analyzed for activated microglia by 
immunohistochemical staining with antibodies to Iba-1 at post-onset day 7 of the 
study. Digitized images covering the entire cross-sectional area from 5 – 6 
lumbar spinal regions from each mouse in the study were quantitated for 
staining, which revealed diminished numbers of Iba-1-positive cells in the spinal 
cords of CAPE-treated animals versus vehicle. Values represent the mean ± 
SEM. Statistical analysis was performed using one-way ANOVA. **, p < 0.01; n = 
4, WT; n = 6, vehicle, n = 8 CAPE. 
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2.5.9.  CAPE treatment of symptomatic SOD1G93A mice resulted in decreased 
expression of cleaved α-II spectrin in spinal cords 
 Because the activity of the Ca2+-activated protease, calpain, was found to 
be increased in the spinal cord of SOD1G93A mice (Stifanese et al., 2010), the 
effect of CAPE treatment on the calpain system in SOD1G93A mice was explored 
by measuring expression of a known cleavage target of calpain, α-II spectrin 
(Strong, 1999). After 3 days post-onset, expression of cleaved α-II spectrin was 
significantly decreased in symptomatic mice receiving CAPE treatment (0.31 ± 
0.006, n = 3; *** p < 0.005) and wild type controls (0.38 ± 0.03, *** p < 0.005) as 
compared to mice without CAPE (0.61 ± 0.06, n = 3) as demonstrated in a 
representative immunoblot (Fig 2.11a) and quantified band density 
measurements (Fig 2.11b). Actin levels were unchanged in all groups. 
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a. 
 
b. 
 
Figure 2.11. CAPE treatment for 3 days decreased α-II spectrin cleavage in 
symptomatic SOD1G93A mice. 
 
SOD1G93A mice were given 10 mg/kg CAPE or vehicle for 3 days and spinal 
cords were removed for Western blot as described in Experimental Procedures. 
Actin expression was unchanged in all groups and used as an internal loading 
control. (a) Representative immunoblots and (b) quantitation of bands revealed a 
decrease in cleaved α-II spectrin expression at 3 days post-onset when CAPE 
treatment was given. Wild type, n = 5; vehicle, n = 3; CAPE, n = 3. *** p < 0.005. 
Data are group averages ± SEM. 
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2.5.10.  CAPE treatment decreased expression of cleaved caspase-12 in spinal 
cords of SOD1G93A mice with disease onset 
 Endoplasmic reticulum (ER) stress is posited to be implicated in the motor 
neuron death observed in SOD1G93A mouse spinal cord (Wootz et al., 2004, 
2006). In order to examine the effect of CAPE treatment on a component of the 
ER stress cascade, caspase-12 (Wootz et al., 2004), spinal cords that were 
removed from symptomatic SOD1G93A mice were analyzed via Western blot. After 
3 days following disease onset, there was a significant decrease in cleaved 
caspase-12 expression in SOD1G93A mice given CAPE treatment for 3 days (0.62 
± 0.004, n = 3, *** p < 0.005) and wild type controls (0.42 ± 0.005, *** p < 0.005) 
versus their vehicle-treated counterparts (0.80 ± 0.02, n = 3) as shown in 
representative blots (Fig 2.12a) and quantitative analyses of band densities (Fig 
2.12b). Levels of actin were unchanged regardless of CAPE and genotype.  
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a.  
  
 
b. 
 
Figure 2.12. CAPE treatment had no effect on cleaved caspase-12 
expression in SOD1G93A mice at 3 days post-onset. 
 
SOD1G93A mice were given 10 mg/kg CAPE or vehicle for 3 days and spinal 
cords were removed for Western blot as described in Experimental Procedures. 
Unchanged actin expression in all groups served as an internal loading control. 
(a) Representative immunoblots and (b) quantification of band densities showed 
no difference in caspase-12 cleavage with or without CAPE treatment for 3 days. 
Wild type, n = 5; vehicle, n = 3; CAPE, n = 3. *** p < 0.005. Data are group 
averages ± SEM. 
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2.6.  Discussion 
This preclinical study sought to validate a candidate small molecule for 
ALS therapy by employing experimental systems approximating a clinical 
treatment scenario. Most importantly for clinical translation, the effectiveness of 
CAPE was examined when administered after disease symptoms developed in 
the well-established SOD1G93A mouse model of ALS (Gurney et al., 1994). The 
results from this study demonstrate that post-onset, daily oral administration of 
CAPE at a dose of 10 mg/kg was effective in delaying disease progression and 
prolonging survival. These findings are consistent with previous studies from this 
laboratory demonstrating potent neuroprotective activity of CAPE both in vivo 
and in vitro in various neurodegenerative disease models (Wei et al., 2004; Ma et 
al., 2006; Wei et al., 2008). Taken together, the present findings and previous in 
vitro and in vivo studies from this laboratory suggest that CAPE has high 
potential as a therapeutic compound for neurodegenerative diseases. 
In the vast majority of sporadic ALS cases the etiology is unknown; 
although, pathological data from human patients as well as mouse models 
suggest that disease sequelae are promoted by accumulation of tissue derived 
toxins that disrupt homeostatic functions. Implicated toxins and pathologic 
processes are glutamate excitotoxicity, reactive oxygen species, mitochondrial 
injury, inflammation propagated by neighboring cells (for example, glia), 
dysfunctional axonal transport, endoplasmic reticulum stress, vascular 
dysfunction, proteosome inhibition, synaptic defects, loss of barrier function 
between peripheral and central nervous tissues, and toxic peptide conformations 
108 
 
(Ilieva et al., 2009). It is not currently known which of these processes are 
primary to disease onset and progression and which are secondary events due 
to disease state; thus, hindering development of disease-targeted therapies. This 
lack of a clear understanding of ALS pathophysiology may partially explain the 
many failures in the clinic of therapeutic modalities that demonstrated clear 
potential in preclinical testing (Gurney et al., 1998). 
Although the uncertainties regarding the molecular basis of ALS hinder 
development of disease modifying therapies, it is formally possible that agents, 
such as CAPE, which block major neurodegenerative pathways resulting from 
the initial insult(s), will be efficacious in preventing disease progression. In fact, 
the extension of post-onset lifespan correlated with a significantly greater number 
of surviving motor neurons in the lumbar spinal cord after 7 days of CAPE 
treatment. Also observed was a decreased number of activated microglia and 
astrocytes in the lumbar region of the spinal cord, suggesting that CAPE may 
exert some of its protective effects through repressing inflammatory and cell 
death processes. This was corroborated by reduced levels of activated p38 
MAPK, which is part of an important signal transduction pathway that contributes 
to neuronal death and inflammation (Cuenda et al., 2007) in spinal cords of 
CAPE-treated SOD1G93A mice (Dewil et al., 2007).  
Current evidence suggests that p38 mitogen activated protein kinase 
(MAPK) may be involved in motor neuron cell death in theSOD1G93A mouse 
(Bendotti et al., 2004; Wengenack et al., 2004; Dewil et al., 2007). Activated 
(phosphorylated) p38 MAPK was upregulated in spinal cords of SOD1G93A mice 
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(Tortarolo et al., 2003; Bendotti et al., 2004; Wengenack et al., 2004) and human 
ALS patients (Hu et al., 2003). Furthermore, chemical inhibition of the p38 MAPK 
pathway increased motor neuron survival and reduced microglial activation in 
SOD1G93A mouse spinal cord (Dewil et al., 2007), suggesting the dual pathogenic 
role of the p38 MAPK pathway in ALS motor neuron cell death and 
neuroinflammation. In our previous studies, CAPE protected against glutamate 
excitoxicity and reduced p38 phosphorylation (Wei et al., 2008). Previous studies 
from this laboratory reported that CAPE was able to attenuate the increase in 
phospho-p38 levels observed in glutamate-induced cerebellar granule neuronal 
death (Wei et al., 2008), demonstrating reduction of phospho-p38 played a key 
role in CAPE-induced neuroprotection against glutamate neurotoxicity 
(excitotoxicity). Additionally, glutamate-induced transient activation of p38 MAPK 
in microglia has been also strongly linked to glutamate neurotoxicity in mixed 
neuronal cultures, indicating the involvement of phosphor-p38 in neuronal death-
related inflammation (Tikka et al., 2001). Since it has been confirmed that 
excitotoxicity plays an important role in ALS pathogenesis, CAPE-induced 
decreases in phospho-p38 levels in symptomatic SOD1G93A mice may play an 
important role in attenuation of the neuroinflammatory events and motor neuron 
death observed in ALS and disease progression.  
The onset of motor neuron excitotoxic death and oxidative stress has 
been proposed to induce neuroinflammatory responses, such as elevations in 
pro-inflammatory cytokines in the CNS (Almer et al., 2001; Wu et al., 2006) and 
astrocyte (Yamanaka et al., 2008) and microglia activation (Boillee et al., 2006b), 
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which are thought to play key roles in ALS progression and motor neuron death 
and are pathogenic hallmarks of this disease (Rowland and Shneider, 2001).  
The anti-inflammatory and anti-cell death effects of CAPE observed in this 
study and posited to occur via downregulation of phospho-p38 in the SOD1G93A 
mouse model were predicted based on similar properties in other 
neurodegenerative models (Wei et al., 2004; Noelker et al., 2005; Ma et al., 
2006), which share many common molecular and cellular pathogenic events with 
ALS such as free radical production (Bossy-Wetzel et al., 2004). Thus, the motor 
neuron protection, anti-inflammation, and attenuated glial activation observed in 
CAPE-treated SOD1G93A mice may also involve a reduction in free radical 
generation and other anti-oxidative damage mechanisms. 
Calpain activity has been observed to be increased in the SOD1G93A 
mouse (Wootz et al., 2006; Stifanese et al., 2010) due to increased levels of 
calcium in the cytosol caused by excitotoxicity (Roy et al., 1998; Tradewell and 
Durham, 2010). Activated calpains target and cleave cytoskeletal proteins, such 
as α-II spectrin; calpain cleavage activity results in the accumulation of α-II 
spectrin and formation of inclusions located in motor neurons (Stifanese et al., 
2010). Inhibition of calpain via expression of its endogenous inhibitor, calpastatin, 
slowed degeneration of SOD1G93A motor neurons (Tradewell and Durham, 2010). 
CAPE treatment of symptomatic SOD1G93A mice resulted in the decreased 
expression of a cleaved calpain target, α-II spectrin, in the spinal cord, 
suggesting that CAPE’s neuroprotection involves inhibition of calpain activation. 
Additionally, α-II spectrin was also shown to be a substrate for caspase-3 
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cleavage (Siman et al., 1989; Wang et al., 1998; Roberts-Lewis and Siman, 
1993). Thus, CAPE’s blockage of α-II spectrin cleavage may be via inhibition of 
both calpain and caspase-3 activity. 
Endoplasmic reticular (ER) stress is also thought to play a role in the 
motor neuron degeneration observed in ALS. Found in association with ER 
stress were elevated levels of cleaved and activated caspase-12 (Nagata et al., 
2007). In ALS, ER stress is thought to be caused by excitotoxicity-induced 
oxidative damage (Ilieva et al., 2007). CAPE treatment of SOD1G93A mice with 
disease onset resulted in decreased levels of cleaved caspase-12 in the spinal 
cord. Because caspase-12 activation and cleavage is an event downstream from 
excitotoxicity, oxidative damage, and ER stress, it may be possible that CAPE is 
able to exert its neuroprotection via anti-excitotoxic, anti-oxidative, or anti-ER 
stress mechanisms. 
The neurologic benefit of CAPE treatment may be a result of the 
compound’s ability to simultaneously modulate multiple pathways, such anti-
inflammation and anti-neuron cell death, thereby, providing a more effective 
blockade of disease progression. Previous potential candidates ALS treatments, 
such as Coenzyme Q10 (an anti-oxidant), topiramate (an anti-epileptic drug that 
blocks glutamate excitoxicity) and celecoxib (a non-steroidal anti-inflammatory 
drug), target individual pathways and had no beneficial effect in ALS patients 
despite promising results when used with animal models (Cudkowicz et al., 2003, 
2006; Kaufmannet al., 2009). It is plausible that the ineffectiveness of these 
compounds in the more complex human disease relates to their capacity to 
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mainly modulate a single pathogenic mechanism. However, it should be noted 
that although CAPE acts very fast after it is administrated immediately after 
onset, its neuroprotective efficacy is not as strong as we expected. Our 
observations found that after seven to fourteen-day’s significant improvement in 
mouse behavior, mice deteriorate very quickly. Our hypothesis is that after 7 – 14 
days of treatment, CAPE may lose its ability to block several pathways known to 
contribute to neuronal death, resulting in neurons dying by alternative death 
pathways. This phenomenon is very common in in vitro neuroprotective studies. 
Currently, there is no treatment able to completely abolish cell death. 
Additionally, although CAPE has multiple capabilities, including anti-
inflammatory, anti-oxidant, and anti-cell death functions, CAPE may be unable to 
exert effects on currently unknown neurodegenerative events contributing to 
disease progression as the definitive spectrum of neuronal death pathways has 
yet to be elucidated in ALS and the G93A mouse model, allowing for motor 
neuron cell death to continue via alternative, short-cut pathways to those blocked 
by CAPE. 
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CHAPTER 3:  EXPLORATORY STUDY - Adipose-derived Stem Cell Conditioned 
Media Extends Survival of a Mouse Model of Amyotrophic Lateral Sclerosis 
 
3.1.  Rationale 
Caffeic acid phenethyl ester (CAPE) treatment was previously found by 
this laboratory to be neuroprotective in a neonatal rat model of hypoxia-ischemia 
(Wei et al,. 2004). CAPE’s protective abilities were related to its anti-
inflammatory, anti-oxidant, and anti-cell death properties. The previous chapters 
centered upon the use of one compound (CAPE) with two etiologically and 
neuropathologically different animal models of neurodegeneration, the MPTP and 
SOD1G93A mice. These data provide evidence that if two diseases share multiple 
downstream pathways and a compound is able to target those downstream 
pathways, then the compound will be effective against progression of both 
diseases. 
Recent studies by this laboratory have demonstrated that adipose-derived 
stem cell conditioned media (ASC-CM) is neuroprotective in an in vivo model of 
neurodegenerative disease, a neonatal rat model of hypoxia-ischemia (Wei et al., 
2009). This pilot study was designed to determine the effects of ASC-CM 
treatment in a genetic animal model of neuronal death, the SOD1G93A mouse, as 
ASC-CM was found to be neuroprotective in an injury-induced animal model of 
neuronal death, the hypoxia-ischemia neonatal rat (Wei et al., 2009). 
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3.2  Introduction 
For a complete review, please see Section 2.3.1. Amyotrophic Lateral Sclerosis 
of Chapter 2. 
 
3.3.  Experimental Procedures 
 For all protocols, please refer to Section 2.4. Experimental Procedures of 
Chapter 2. 
 
3.3.1.  Animal Treatment Protocol 
 Adipose-derived stem cell media (ASC-CM) was made as previously 
described (Wei et al., 2009) and injected intraperitoneally (i.p.) at a volume of 
200 µL, once daily. Animals in the vehicle group Basal Media Eagle (BME) alone 
were given an equivalent injection volume as ASC-CM-treated mice. Mice 
received one daily dose of ASC-CM or vehicle until a humane endpoint near 
death (survival studies) or for 3 or 7 days after disease onset (biochemical and 
immunohistochemical studies). 
 
Figure 3.1. Diagram of the Animal Treatment Protocol. 
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3.4.  Results 
3.4.1.  Post-onset ASC-CM treatment of SOD1G93A mice significantly diminished 
symptomatic progression and extended life span 
 SOD1G93A mice were given ASC-CM treatment from disease onset until a 
humane time point near death (death endpoint). The length of time from disease 
onset until death was measured and reported as days of post-onset survival (Fig 
3.2A). The SOD1G93A mice given ASC-CM had increased post-onset survival 
times (31.6 ± 4.1 days, n = 5; *** p < 0.005) as compared to vehicle-treated mice 
(16.1 ± 1.6 days, n = 7). This increase in survival translated into an extension of 
SOD1G93A mice lifespans (Fig 3.2B). ASC-CM-treated mice had significantly 
longer lifespans (138.8 ± 3.1 days, n = 5) versus the vehicle counterparts (124.4 
± 1.5 days, n = 7).  
 
 
 
  
116 
 
 
 
 
Figure 3.2A.  Treatment with ASC-CM extends post-onset survival of 
SOD1G93A mice. 
 
Male and female symptomatic SOD1G93A mice were given daily ASC-CM 
treatment or vehicle until the death endpoint. Duration of disease is reported as 
days of post-onset survival and measured by the number of days between 
disease onset and a humane endpoint near death. Mice with disease onset who 
were treated daily with ASC-CM (n = 7) had a significant extension of survival 
time as compared to SOD1G93A mice without ASC-CM (n = 5). The calculated 
averages (± SEM) of post-onset survival were significantly increased in mice 
given ASC-CM compared to vehicle. Statistical analysis was performed using 
one-way ANOVA. ***, p < 0.005 vs. vehicle. 
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Figure 3.2B.  ASC-CM treatment lengthens the lifespan of SOD1G93A mice 
with disease onset. 
 
Male and female SOD1G93A mice with disease onset were treated with ASC-CM 
or vehicle until the death endpoint. The number of days between birth and a 
humane endpoint near death were measured in days of lifespan . ASC-CM-
treated mice with disease onset (n = 5) had a significant lifespan extension when 
compared to SOD1G93A mice with no ASC-CM treatment (n = 7). Extended post-
onset survival times of ASC-CM-treated mice resulted in the marked lengthening 
of lifespan relative to vehicle mice. ***, p < 0.005 vs. vehicle. 
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3.4.2.  A greater number of motor neurons in the lumbar spinal cord survived with 
ASC-CM treatment 
 It was determined whether the extended survival of ASC-CM-treated 
SOD1G93A mice correlated with prevention of motor neuron loss. Motor neuron 
number changes at 7 days following onset were evaluated in cross-sections of 
lumbar spinal cords of the SOD1G93A mice (Fig 3.3A). Vehicle-treated mice 
exhibited a marked (*** p < 0.005) loss of ventral horn motor neurons in the 
lumbar region versus wild type littermates (group means: 7.8 ± 0.84 and 21.9 ± 
0.79, respectively; Fig 3.3B). The loss of motor neurons was prevented at this 
time point by ASC-CM treatment (15.9 ± 2.0, p < 0.01 vs. vehicle); however, 
there was still significant motor neuron loss (p < 0.05) compared to age-matched, 
wild type mice, although this loss is not as severe as in the vehicle group (Fig 
3.3B). MAP2-immunoreactive neuronal processes were observed and clearly 
defined throughout the tissue sections from wild type and ASC-CM-treated mice. 
In contrast, there was very little to no presence of MAP2-positive neuronal 
processes visible in vehicle-treated SOD1G93A mice spinal cord (Fig 3.3A). 
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Figure 3.3A.  ASC-CM 7-day treatment of SOD1G93A mice with disease 
resulted in a greater number of motor neurons present in lumbar spinal. 
 
Symptomatic SOD1G93A mice were given ASC-CM or vehicle for 7 days. Motor 
neurons in the lumbar spinal cord area were identified by immunoreactivity to 
MAP2 antibody and hematoxylin nuclear counterstaining as described in Chapter 
2’s Experimental Procedures section. Representative images of stained lumbar 
spinal cord sections showed an increase in the presence of MAP2-positive 
neurons in lumbar spinal cord of SOD1G93A mice treated with ASC-CM compared 
to vehicle. Scale bars: 100 µm. 
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Figure 3.3B.  A greater number of motor neurons were observed in lumbar 
spinal cords of SOD1G93A mice treated with ASC-CM for 7 days. 
 
Symptomatic SOD1G93A mice were treated with or without ASC-CM for 7 days. 
Digitized images covering the entire cross-sectional area from 6 – 8 lumbar 
spinal regions from each mouse in the study were quantitated for MAP2 
immunoreactivity and hematoxylin nuclear counterstain. With ASC-CM treatment, 
a higher number of motor neurons was observed in SOD1G93A mice with disease 
onset (n = 5) versus vehicle (n = 5). Wild type control data were generated from 4 
mice. Experimental group data are presented as averages (+ SEM) and 
statistical analyses were performed using one-way ANOVA. * p < 0.05; ***, p < 
0.005. 
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3.4.3.  Administration of ASC-CM had no effect on mouse SOD1wild type and 
mutant human SOD1G93A expression in spinal cords of SOD1G93A mice 
 Studies have shown that the transgene copy number (copies of the 
transgene with the G → A at position 93, human mutant form of SOD1) affects 
survival of the SOD1G93A mouse (Alexander et al., 2004b). In order to determine if 
ASC-CM has an effect on SOD1 gene expression, immunoblot analyses were 
performed on spinal cord homogenates after 7 days of ASC-CM treatment (Fig 
3.4a). Band density measurements showed that levels of both wild type 
endogenous mouse SOD1 (mSOD1WT) and mutated human SOD1 (hSOD1G93A) 
expressed exhibited no differences with or without 7-day ASC-CM treatment (Fig 
3.4b). “Wild type/WT” mice express wild type endogenous mouse SOD1 
(mSOD1WT) but do not carry the mutated human SOD1 (hSOD1G93A) transgene; 
“vehicle” and “ASC-CM” mice are the experimentally-treated SOD1G93A 
transgenic mice that express wild type endogenous mouse SOD1 (mSOD1WT) in 
addition to the mutated human SOD1 (hSOD1G93A) transgene. Actin levels 
remained unchanged and served as an internal loading control for endogenous 
mouse SOD1 (mSOD1WT). There were differences in endogenous mouse SOD1 
(mSOD1WT) levels, which then served as an internal control for mutated human 
SOD1 (hSOD1G93A) expression. 
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a. 
 
 
 
b. 
 
 
 
Figure 3.4.  Treatment with ASC-CM did not affect expression of 
endogenous mouse wild type SOD1 and mutated human SOD1 transgene 
in spinal cord. 
 
Wild type control (“WT”) and SOD1G93A mice (“vehicle” and “ASC-CM”) spinal 
cords were prepared as detailed in Chapter 2’s Experimental Procedures. Levels 
of actin were unchanged and used as an internal loading control for endogenous 
mouse wild type SOD1 (“mSOD1WT”). There was no difference in mSOD1WT 
levels, which was the loading control for mutated human SOD1 (“hSOD1G93A”). 
After 7 days of ASC-CM treatment, there was no change in expression of either 
endogenous mouse wild type SOD1 or human SOD1 carrying the G93A mutation 
in symptomatic SOD1G93A mice. n = 3 per group. 
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3.4.4.  Daily ASC-CM treatment decreased phosphorylation of p38 MAP kinase 
in spinal cords of SOD1G93A mice 
 It has been demonstrated that motor neuron loss occurs partly through the 
action of activated inflammatory cells in the surrounding area (Boillee et al., 
2006a). In order to determine if the protection of motor neurons following ASC-
CM treatment is due to inflammatory pathway inhibition, levels of phosphorylated 
p38 in spinal cords were evaluated at 3 days (Fig 3.5A) and 7 days (Fig 3.5B) 
following disease onset and with or without ASC-CM administration during that 
time period. In agreement with other reports using the SOD1G93A mouse (Hu et 
al., 2003; Dewil et al., 2007), p38 phosphorylation was elevated in SOD1G93A 
mice after disease onset at both 3 days (0.84 ± 0.0092, p < 0.005 vs. wild type 
and ASC-CM; Fig 3.5Ab) and 7 days post-onset (1.3 ± 0.17, p < 0.01 vs. wild 
type; Fig 3.5Bb). Levels of phospho-p38 protein in the spinal cords were 
significantly decreased with ASC-CM treatment for 3 days (0.69 ± 0.023, p < 
0.005 vs. vehicle and wild type; Fig 3.5Ab) and for 7 days (0.56 ± 0.23, p < 0.05 
vs. vehicle; Fig 3.5Bb) as compared to the vehicle groups. These phospho-p38 
levels observed in ASC-CM-treated animals were still higher than wild type 
controls at 3 days (0.38 + 0.062, p < 0.005 vs. ASC-CM group; Fig 3.5Bb). 
 
 
  
124 
 
 
a. 
 
 
 
b. 
 
 
 
Figure 3.5A.  Reduced phosphorylation of p38 in spinal cords of SOD1G93A 
mice with disease onset was observed after 3 days of ASC-CM treatment. 
 
SOD1G93A mice with onset received ASC-CM or vehicle for 3 days and spinal 
cords were prepared for Western blot as described in Experimental Procedures. 
(a) Representative Western blots and (b) quantitation of band density showed 
reduced phosphorylated-p38 expression in spinal cords of SOD1G93A mice given 
ASC-CM versus vehicle. Unchanged total p38 expression served as an internal 
loading control. Values are the mean density ± SEM. One-way ANOVA was used 
for statistical analysis. ***, p < 0.005; n = 3 per group. 
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a. 
 
b. 
 
 
 
Figure 3.5B. Decreased levels of phospho-p38 in spinal cords of 
symptomatic SOD1G93A mice were observed after 7 days of ASC-CM 
treatment. 
 
Symptomatic SOD1G93A mice were given ASC-CM or vehicle for 7 days and 
spinal cords were harvested for Western blotting as described in Experimental 
Procedures in Chapter 2. (a) Representative immunoblots and (b) densitometric 
quantitation demonstrated reduced phosphorylated p38 expression with ASC-CM 
treatment as compared to vehicle-treated animals. Unchanged total p38 levels 
served as an internal loading control. Values represent the mean density ± SEM. 
Statistical analysis was performed using one-way ANOVA. * p < 0.05; ** p < 0.01; 
n = 3 per group. 
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3.4.5.  A reduction in GFAP expression was observed in the spinal cords of 
symptomatic SOD1G93A mice treated with ASC-CM 
 Because treatment with ASC-CM was showing significant neuroprotection 
of motor neurons potentially via anti-inflammatory mechanisms thus far, glial 
activation after treatment with ASC-CM was examined to further explore this 
possibility. Expression of GFAP was measured in the spinal cords of SOD1G93A 
mice after 3 days of treatment with ASC-CM or vehicle. Representative 
immunoblots demonstrated that there is significantly reduced GFAP expression 
with ASC-CM treatment (0.89 ± 0.027) versus vehicle (1.2 ± 0.020; *** p < 0.005; 
Fig 3.6a). The GFAP levels observed in the ASC-CM-treated group were 
comparable to that of the wild type controls (0.95 ± 0.034). 
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a. 
   
b. 
 
 
 
Figure 3.6.  3-day treatment with ASC-CM showed reduced GFAP 
expression in spinal cords of symptomatic SOD1G93A mice. 
 
SOD1G93A mice with disease onset were given ASC-CM or vehicle for 3 days. 
Spinal cords were removed for immunoblot as described in Experimental 
Procedures. Actin expression remained unchanged in all groups and served as 
an internal loading control. (a) Representative immunoblots and (b) band 
quantitation demonstrated a decrease in spinal cord GFAP expression after 3-
day ASC-CM treatment as compared to vehicle. Experiments were completed in 
triplicate with n = 3 per group. * p < 0.05; *** p < 0.005. 
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3.4.6.  Administration of ASC-CM to SOD1G93A mice with disease onset 
decreased CD11b expression in spinal cords 
 In order to further investigate glial activation after ASC-CM treatment, 
spinal cords were prepared for Western blot and examined for expression of 
CD11b, a glial marker found to be induced by neuroinflammation (Boillee et al., 
2006). CD11b expression was observed at 3 days (Fig 3.7A) and 7 days (Fig 
3.7B) after ASC-CM or vehicle treatment. After 3 days of ASC-CM treatment of 
symptomatic SOD1G93A mice, representative immunoblots (Fig 3.7Aa) and 
measurements of band densities (Fig 3.7Ab) demonstrated no differences in 
CD11b expression in all groups (group averages ± SEM: 0.27 ± 0.065 for wild 
type; 0.28 ± 0.050 for vehicle; 0.24 ± 0.067 for ASC-CM). However, after 7 days 
of ASC-CM treatment, representative immunoblots (Fig 3.8Ba) and band density 
quantitation (Fig 3.8Bb) demonstrated a significant increase in CD11b expression 
in the spinal cord of vehicle mice (0.83 ± 0.049 for vehicle, *** p < 0.005 versus 
wild type and ASC-CM) when compared to ASC-CM-treated animals (0.50 ± 
0.078), whose CD11b expression level was at a similar level to wild type mice 
(0.46 ± 0.023) after 7 days.  
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a. 
 
 
 
b. 
 
 
 
Figure 3.7A.  3 days of ASC-CM treatment had no effect on CD11b 
expression in spinal cords of symptomatic SOD1G93A mice. 
 
SOD1G93A mice were given 3 days of ASC-CM treatment or vehicle upon disease 
onset. Spinal cords were processed Western blot as described in Experimental 
Procedures. Unchanged actin in all groups served as an internal loading control. 
(a) The representative immunoblots and (b) band densities that were measured 
showed no change in spinal cord CD11b expression after 3 days of ASC-CM 
treatment. WT (wild type), n = 3; vehicle, n = 4; ASC-CM, n = 4. 
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a. 
 
 
 
b. 
 
 
 
Figure 3.7B.  ASC-CM treatment for 7 days reduced expression of CD11b in 
spinal cords of SOD1G93A mice with disease onset. 
 
For 7 days, symptomatic SOD1G93A mice were given ASC-CM or vehicle. Spinal 
cords were removed for immunoblot as described in Experimental Procedures. 
Unchanged actin expression served as an internal loading control. (a) 
Representative immunoblots and (b) band quantitation demonstrated a decrease 
in spinal cord CD11b expression after 7 days of ASC-CM treatment as compared 
to vehicle. WT (wild type), n = 3; vehicle, n = 3; ASC-CM, n = 3. *** p < 0.005. 
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3.4.7.  ASC-CM treatment of symptomatic SOD1G93A mice resulted in decreased 
expression of α-II spectrin in spinal cords 
 Activity of the Ca2+-activated protease, calpain, was increased in 
SOD1G93A mice spinal cords (Stifanese et al., 2010). ASC-CM’s effect on the 
calpain system in SOD1G93A mice was determined by measuring expression of α-
II spectrin, a known cleavage target of calpain (Strong, 1999). After 3 days 
following disease onset, cleaved α-II spectrin expression was significantly 
decreased in SOD1G93A mice receiving ASC-CM treatment (0.17 ± 0.03, n = 4; *** 
p < 0.005) and wild type controls (0.16 ± 0.01, *** p < 0.005) as compared to 
mice given vehicle (0.99 ± 0.003, n = 3), which was demonstrated in a 
representative immunoblot (Fig 3.8a) and quantified band density measurements 
(Fig 3.8b). Levels of actin remained unchanged for all groups and were used as 
internal loading controls. 
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a. 
  
b. 
 
 
Figure 3.8.  ASC-CM treatment for 3 days decreased α-II spectrin cleavage 
in symptomatic SOD1G93A mice. 
 
SOD1G93A mice were given ASC-CM or vehicle for 3 days and Western blot 
analysis was done as described in Chapter 2’s Experimental Procedures. 
Unchanged actin expression served as an internal loading control. (a) 
Representative immunoblots and (b) quantitation of band densities revealed a 
decrease in cleaved α-II spectrin expression at 3 days post-onset when ASC-CM 
treatment was given. Wild type, n = 5; vehicle, n = 3; ASC-CM, n = 4. *** p < 
0.005. 
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3.4.8.  ASC-CM treatment had no effect on caspase-12 cleavage in spinal cords 
of SOD1G93A mice with disease onset 
 Because ER stress is thought to play a role in motor neuron death in 
SOD1G93A mouse spinal cord (Wootz et al., 2004, 2006), spinal cords were 
examined for the effect of ASC-CM treatment on caspase-12, an ER stress 
pathway component (Wootz et al., 2004). Spinal cords were removed from 
symptomatic SOD1G93A mice and analyzed via Western blot. At 3 days after 
disease onset, there was a significant decrease in cleaved caspase-12 
expression in symptomatic SOD1G93A mice injected with ASC-CM for 3 days 
(0.47 ± 0.09, * p < 0.05) and wild type controls (0.53 ± 0.006, *** p < 0.005) 
versus their vehicle-treated counterparts (0.74 ± 0.01) as shown in representative 
blots (Fig 3.9a) and quantitative analyses of band densities (Fig 3.9b). Actin 
levels were not changed regardless of CAPE treatment and genotype and used 
as an internal control.  
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a. 
 
 
 
 
b. 
  
Figure 3.9.  ASC-CM treatment for 3 days decreased caspase-12 cleavage in 
symptomatic SOD1G93A mice. 
 
SOD1G93A mice were given ASC-CM or vehicle for 3 days and spinal cords were 
removed for Western blot as described in Chapter 2’s Experimental Procedures. 
Actin expression was unchanged in all groups and used as an internal loading 
control. (a) Representative immunoblots and (b) band density quantitation 
showed no difference in caspase-12 cleavage with or without ASC-CM treatment. 
n = 4 per group; * p < 0.05; *** p < 0.005. Data are group averages ± SEM. 
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3.5  Discussion 
This exploratory study was designed to confirm the effects of a 
biologically-derived reagent on an ALS animal model that is clinically relevant 
such that treatment was applied after disease onset was established in the 
widely used SOD1G93A mouse model (Gurney et al., 1994). The data collected 
from this pilot study demonstrate the effectiveness of ASC-CM treatment in 
prolonging post-onset survival and extending the lifespan of the symptomatic 
SOD1G93A mouse. These results are in agreement with previous studies from this 
laboratory demonstrating that treatment with ASC-CM is beneficial and protective 
of neurons in vivo during neuronal injury or challenge, such as in the hypoxic-
ischemic rat neonatal brain (Wei et al., 2009). The findings from this exploratory 
study and the previous in vivo studies suggest that ASC-CM has potential as a 
therapeutic for neuronal degeneration. 
Although the etiology of sporadic ALS is currently unknown, through the 
use of animal models and correlation with neuropathological findings from human 
ALS patients, several key mechanisms of neuronal death have been proposed to 
disrupt normal motor neuron function and lead to their degeneration. Current 
studies implicate glutamate-induced excitotoxicity, mitochondrial dysfunction, 
oxidative stress, neuroinflammation, aberrant axonal transport systems, 
endoplasmic reticulum (ER) stress, inhibition of proteosomal function, 
compromised blood-brain barrier, and abnormal protein aggregation (Ilieva et al., 
2009). There is much debate as to which processes contribute towards disease 
etiology and which events are secondary to the established disease state. This 
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presents ALS drug development with difficulties as neuropathology-specific 
targeting of treatment may be ineffective. 
Despite the mechanistic uncertainties underlying events leading to ALS 
neuropathologic changes, treatments like ASC-CM may prove to be beneficial as 
they are able to block or modify several neuronal death pathways due to the 
heterogeneity in their composition. ASC-CM has been found to contain a 
multitude of neurotrophic factors such as insulin-like growth factor (IGF-1) and 
brain-derived neurotrophic factor (BDNF), which could be beneficial for the 
diseased motor neuron (Wei et al., 2009). After 7 days of treatment with ASC-
CM, symptomatic SOD1G93A mice had significant prolongation of post-onset 
survival times, which translated into an overall extension of lifespan. Additionally, 
this lengthened of post-onset lifespan following ASC-CM administration was 
correlated with markedly higher numbers of surviving motor neurons in the 
lumbar area of the spinal cord. Further examinations at the cellular level 
determined that the increase in motor neuron survival after ASC-CM treatment 
was accompanied by decreased expression of glial activation markers and 
reductions in levels of phosphorylated p38 MAP kinase, which are important 
components of the neuroinflammation pathway (Cuende et al., 2007) contributing 
to neuronal death in the spinal cords of SOD1G93A mice (Dewil et al., 2007). 
Other pilot data from this study show lower levels of cleaved α-II spectrin, which 
is a known substrate of both calpains and caspase-3 (Simon et al., 1989; Wang 
et al., 1998). Decreased cleavage of α-II spectrin in the spinal cords of ASC-CM-
treated SOD1G93A mice may indicate that this biologically-derived reagent has 
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protective effects against glutamate-induced apoptotic mediators (Wootz et al., 
2006; Stifanese et al., 2010; Tradewell and Durham, 2010). A reduction in 
cleaved caspase-12 expression was also observed in the spinal cords of 
SOD1G93A mice given ASC-CM treatment, suggesting that treatment with this 
biological agent may be effective in reducing ER stress associated with ALS 
(Nagata et al., 2007). 
Taken together, this exploratory study demonstrated that ASC-CM 
provides significant neuroprotection in the SOD1G93A mouse model of ALS. This 
protective ability may reside in the individual actions of its neurotrophic 
components working separately or in concert towards the preservation of motor 
neurons in the spinal cord as well as attenuation of the neuropathogenic 
mechanisms underlying motor neuron death and disease progression. 
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CHAPTER 4: General Conclusions 
4.1  Summary 
The study in Chapter 1 reports that oral administration of CAPE in mice 
prevents MPTP-induced neuronal death and the loss of striatal DA, accompanied 
by inhibition of MPTP-induced expression of caspase-1 and iNOS in vivo. 
Additionally, in contrast to minocycline treatment (Tipton and Singer, 1993), 
CAPE administration directly blocks MPP+-induced neurotoxicity in vitro and this 
action may mediate inhibition of MPP+-induced release of cytochrome c and AIF 
from mitochondria. Collectively, these data provide evidence that CAPE, an 
active component isolated from propolis, has robust neuroprotective activity in 
the MPTP mouse model of Parkinson’s disease. Therefore, CAPE may prove 
effective in altering or preventing the induction of or slowing the progression of 
Parkinson’s disease and related neurodegenerative disorders, such as 
amyotrophic lateral sclerosis. 
The study in Chapter 2 presents the potential for a treatment with a small 
molecule compound that acts on multiple pathways (i.e., neuroinflammation, ER 
stress, and cell death) that are putatively involved in and converge towards ALS 
progression. Importantly, these effects were evident when CAPE was 
administered upon symptom onset in the SOD1G93A mouse, which is highly 
correlative to the stage of presentation and disease diagnosis in human patients. 
Data from the current and previous studies from this laboratory suggest that 
CAPE could be a potent pharmacological therapy for ALS and PD as well as 
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other diseases of the brain and spinal cord with shared neuronal death pathways 
and the ensuing neuropathogenic consequences. 
The pilot study in Chapter 3 provides evidence for the potential of using a 
biologically-derived reagent for the treatment for ALS as the neuroprotective 
effects of ASC-CM were demonstrated in its ability to significantly prolong the 
survival of a clinically-relevant animal model of ALS as well as its actions on 
multiple pathways posited to be involved in ALS disease progression. Exploratory 
data from these experiments in combination with previous studies from this 
laboratory suggest that ASC-CM may be effective for the treatment of ALS and 
other neuronal death-related disorders. 
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